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Chemokines serve an integral role in the inflammatory response, specifically through the 
development of a chemotactic gradient which directs the trafficking of inflammatory leukocytes 
to the site of tissue damage or infection. Chemokines exert their effects through interactions 
with both chemokine receptors and glycosaminoglycans (GAGs). 
Targeting chemokines for therapeutic benefit has yielded limited success, likely due to the 
promiscuity of the system, where blocking individual chemokines does not necessarily inhibit 
chemotaxis. Alternately, the use of chemokines as diagnostics/prognostics for cancer, 
inflammatory disease, and autoimmune disease is a more promising area of research. The 
utilisation of chemokine targeting for both diagnostics and therapeutics has classically been 
undertaken utilising antibodies which are monospecific, hence issues may arise with regards to 
chemokine promiscuity.  
Viruses have developed numerous techniques to subvert the host inflammatory response, 
including the secretion of viral chemokine binding proteins (vCBPs). These proteins can exhibit 
binding specificity for multiple classes of chemokines, therefore offering a unique potential for 
use in clinical diagnostics. 
This study investigated the use of a vCBP derived from Orf virus stain NZ2, which binds across 
three classes of chemokines, as a diagnostic tool. The utility of CBP was investigated in assays 
for which antibodies are currently utilised, namely immunofluorescent cytology, western 
blotting, and enzyme-linked immunosorbent assays (ELISA). 
For use in immunofluorescent cytology, a protocol was developed to enable different levels of 
fluorophore conjugation to CBP. The fluorophore utilised was DyLight®594. Fluorophore 
conjugation to CBP was then assessed, indicating the extent of fluorophore conjugation did not 
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impact binding to chemokines across different classes or species, including mouse CCL2 and 
CXCL2, and human CCL2 and CCL5. The ability of fluorophore-conjugated CBP to detect 
chemokines was then assessed in a cell-based inflammatory assay utilising the human monocyte 
cell line THP-1, expressing CCL2 and CCL5 in response to treatment with lipopolysaccharide 
(LPS). The ability of the fluorophore-conjugated CBP to detect chemokines in these cells was 
directly compared with a fluorophore-conjugated anti-CCL2 antibody using immuno-
fluorescent microscopy. Whilst the antibody successfully detected CCL2 in activated THP-1 
cells, the CBP exhibited reduced sensitivity and showed equivalent levels of detection 
irrespective of LPS stimulation. The specificity of chemokine binding exhibited by CBP and 
anti-CCL2 antibody was then assessed via pre-binding with soluble CCL2 and competitive 
inhibition with unlabelled CBP or antibody. Whilst chemokine binding by the fluorophore-
conjugated antibody was affected following pre-binding and competition, neither had a 
substantial impact on CBP binding. The potential of a GAG-CBP interaction was then assessed 
through pre-binding with soluble heparin. The findings indicated that the observed THP-1/CBP 
interaction is mediated, at least in part, through cell-surface GAGs.  
Preliminary investigations into the use of fluorophore conjugated CBP in western blotting 
indicated that CBP is unable to detect denatured CCL2. The use of native CBP was also trialled 
within ELISA protocols, where CBP was shown to both detect capture-antibody bound CCL2, 
and when immobilised successfully captured CCL2 for antibody detection.  
This study suggests that fluorescent conjugation of CBP is easily achievable and does not 
impact protein function.  Although CBP may not detect cellular chemokine expression, the 
findings here are the first to indicate that this specific CBP can bind heparin, and as such may 
have potential as a GAG targeting diagnostic. The use of the native CBP in ELISA protocols 
was also well supported, but its utility across a range of chemokine ELISA platforms needs to 
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Inflammation (or the inflammatory response) is a complex defence mechanism designed to 
protect the body against harmful stimuli, including pathogens, damaged cells, and toxins 
(Punchard et al., 2004). The inflammatory response is the initial action of the immune system 
against infection and injury, acting to remove any potentially harmful stimuli and allowing for 
the commencement of the healing process (Kohn et al., 2013). Inflammation is symptomatically 
characterised by redness, swelling, heat, and pain, mainly due to complex microcirculatory 
events which enhance blood flow towards the afflicted area (Punchard et al., 2004). By 
increasing vascular permeability at the site of damage or infection, the infiltration of essential 
inflammatory mediators is permitted for the required response (Punchard et al., 2004). The later 
mitigation of this response allows for the commencement of healing processes, without any 
impediment caused by pathogens or dead tissue (Punchard et al., 2004). 
The initiation of the inflammatory response can be simplified to key events, commencing with 
the detection of harmful or foreign stimuli, such as a viral pathogen (Kara et al., 2014). Upon 
detection, inflammatory mediators are activated which promote the recruitment of 
inflammatory cells (Kara et al., 2014). The recruitment of inflammatory cells to the site of 
infection leads to the destruction of harmful stimuli (Kara et al., 2014). Realistically, the 
inflammatory response is a hugely intricate cascade of interactive events, characterised by the 
recruitment of varying subsets of inflammatory mediators and cells specifically tailored to 
ensure the destruction of a particular stimuli (Kara et al., 2014). 
The inflammatory response is critical for both homeostatic function and defence of the host, 
however disease can result with disruption or dysregulation. Gathering evidence indicates the 
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involvement of inflammation within the pathologies of almost all disease states (Raman et al., 
2011). Diseases which are primarily driven by excessive inflammation include autoimmune 
diseases and inflammatory diseases, in which inflammation causes damage to the host 
(Haringman et al., 2003). Alternately, there are several diseases of which inflammation plays 
more subdued roles, such as cancers, where the inflammatory response can help potentiate 
cancer growth and development (Keeley et al., 2010). Specifically, the dysregulation of the 
inflammatory response has impacts upon several biological functions within disease 
pathogenesis including; excessive tissue destruction, remodelling, and growth; impeded 
immunity against pathogens; impeded wound healing (Loberg et al., 2007; Rees et al., 2015).  
When the inflammatory response becomes detrimental to health, a multitude of therapeutics 
can be utilised which act to dampen the response and protect against detrimental effects caused 
by excessive inflammation. Common therapeutics include; nonsteroidal anti-inflammatory 
drugs (NSAIDS) such as acetaminophen (paracetamol); and steroid based anti-inflammatory 
drugs, such as corticosteroids (e.g. prednisone) (Jin, 2015; Barnes, 2006). Both NSAIDs and 
corticosteroids work to systemically dampen the inflammatory response in order to mitigate 
disease-induced damage. However, the use of systemic anti-inflammatory drugs can swing the 
homeostatic balance of inflammation from over-activation to suppression, which impedes upon 
crucial biological functions such as wound healing, and fighting infection (Hsu and Katelaris, 
2009). Considering the development of anti-inflammatory therapeutics, the fundamental failure 
is a lack of specificity for the pathological inflammation, as opposed to inflammation for 
homeostatic function. Proposedly, a therapeutic possessing the ability to ameliorate excessive 
inflammation, without disrupting the homeostatic role of the inflammatory response in 
unafflicted areas would provide a most effective treatment (Hsu and Katelaris, 2009).  
With the inflammatory response being a complex and multifactorial process, targeting specific 
factions of the inflammatory cascade could lead to both inhibition of the pathological 
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inflammatory response and the maintenance of the homeostatic role of inflammation. Targeting 
a family of chemoattractant cytokines (chemokines) involved in the recruitment of 
inflammatory cells theoretically may provide a therapeutic which could achieve this currently 
unachievable goal. 
1.2 Chemokines 
Chemokines are a family of chemoattractant cytokines with the primary responsibility of 
recruiting immune and inflammatory cells to the site of infection or damage through chemotaxis 
(Keeley et al., 2010). Chemokines are produced as a response to the detection of invading 
pathogens, such as viral particles, bacteria, and in response to tissue damage. Several cell types 
are capable of producing chemokines including both structural and immune cells (Raman et al, 
2011; Table 1). Chemokines are not only present during tissue damage, as there is some 
constitutive expression of homeostatic chemokines such as CXCL12 which circulates the body, 
possessing varying roles such as homing of leukocytes to lymphatic tissues (Sanchez-Martin et 
al., 2011). 
1.2.i Chemokine structure and function 
Chemokines are small proteins, typically sized between 7 and 10 kDa (Luster, 1998). 
Chemokines have four major classes separated by slight structural differences (Mellado et al., 
2001). Chemokines are categorised based on the precise expression of conserved cysteine 
residue located near the N-terminus of the protein (Mellado et al., 2001). C chemokines are 
characterised by a singular conserved cysteine residue; CC chemokines have two adjacent 
cysteine residues, CXC chemokines have two cysteine residues adjacent to each other with a 
singular, random amino acid in between; and CX3C chemokines have two conserved cysteine 
residues, with three random amino acids between them. The tertiary structure of all chemokines 
is substantially homologous, constituting of a disordered N-terminus, a three-stranded β-sheet, 
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and a C-helix towards the bottom of the proteins (Kufareva et al., 2015). A notable difference 
between chemokine classes is found within dimer formation of these proteins (Kufareva et al., 
2015). Generally, CXC chemokines form dimers via direct interaction of the first β-sheet of 
both proteins, such as CXCL8. Alternately, CC chemokines form dimers through adjacent 
interactions towards the N-terminus of the proteins, which directly involves the conserved 
cysteine residues referred in the chemokine class nomenclature (Kufareva et al., 2015). Lastly, 
the C class chemokine, XCL1, possesses the most divergent 3D structure compared to normal, 
having a four-stranded β-sheet tertiary structure which dimerises through extensive β-sheet 
interactions, with a “head-to-tail” dimer structure (Kufareva et al., 2015. 
Table 1. Characterising expression, interaction, and biological role of several chemokines. 
Modified from Griffith et al. (2014). Multiple Sclerosis (MS), Crohn’s disease (CD), Respiratory syncytial virus (RSV), 
Rheumatoid arthritis (RA), Inflammatory bowel disease (IBD), Non-small cell lung carcinoma (NSCLC), Natural killer (NK) 
cells. 
 
Chemokine Produced by Receptor Cells Attracted Overexpression in 
disease 
References 
C Class      
XCL1 CD8, CD4 T cells XCR1 Dendritic cells 
NK cells 
RA (Lei and Takahama, 
2012) 
CC Class      









MS, CD, Pancreatic 
cancer progression 
(Deshmane et al., 
2009) 
CCL5 T-lymphocytes Macrophages 
Platelets 












CXC Class      
CXCL2 Monocytes Macrophages 
Neutrophils 
CXCR2 Neutrophils 
T cells  
Fibroblasts 
Cancer Angiogenesis (Iida and 
Grotendorst, 1990) 
CXCL4 Platelets CXCR1 Neutrophils  
Fibroblasts 
Monocytes 
RA, Lung Cancer (Lasagni et al., 
2003) 







CD & IBD, NSCLC, RA (Kohidai and Csaba, 
1998) 
CXCL12 Stromal cells (across a 










CX3C Class      
CX3CL1 Endothelial cells CX3CR1 T cells 
Monocytes 
RA (Bazan et al., 1996) 
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Variations in chemokine structures lead to a plethora of chemokine-receptor interactions, 
(Mellado et al., 2001; Table 1). To date, there are over 50 identified chemokines, with 
approximately 20 different chemokine receptors. The miss-match in the number of chemokines 
to receptors leads to the overlapping of ligand-receptor interactions; combined with the capacity 
of chemokines to bind several receptors, results in the understood promiscuity of the 
inflammatory system (Pease and Horuk, 2010; Table 1). This promiscuity leads to the numerous 
variations of chemokine induced inflammatory cell chemotaxis. 
When tissue is damaged chemokines are produced and secreted, resulting in a local increase in 
chemokine concentration, forming what is known as a chemotactic gradient (Proudfoot et al., 
2003) (Figure 1). The formation of this gradient creates a chemical signalling process which 
drives the attraction of other inflammatory cells/leukocytes to the site of damage or infection to 
exert the desired effect via extravasation through endothelium (Figure 1) (Proudfoot et al., 
2003). 
The process is commenced upon a local release of chemokines in response to damage or 
infection (Figure 1) (Luster, 1998). In situations where the skin barrier is damaged, dermal cells 
release chemokines, whereas in response to infection or allergen exposure, infected cells, or the 
immune cells that identify the allergen, mediate chemokine release (Oskeritzian, 2012). 
Upon chemokine release, the chemokines associate with long polysaccharide chains known as 
GAGs found on the cell membrane of most cells (Figure 1) (Garcia et al., 2016).  GAG 
interactions are fundamental for the formation of the chemotactic gradient as they stabilise 
chemokine binding to their receptors (Thompson et al., 2017). Heparin sulphate (HS) is the 
most abundant GAG found on the surface of endothelial cells (Farrugia et al., 2018). Studies 
have indicated that inhibition of HS synthesis significantly decreases the amount of neutrophil 
extravasation through the endothelial wall (Farrugia et al., 2018).  
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The association of chemokines to these GAGs promotes the expression of selectins, which are 
weakly adherent glycoproteins (Barthel et al., 2007). The increased expression of selectins 
leads to the adhesion of circulating (rolling) lymphocytes to the cell surface, which also express 
selectins. GAG-immobilised chemokines presented to chemokine receptors on the surface of 
the leukocyte leads to the cell-surface expression of integrins which facilitate adhesion to the 
endothelium (Figure 1) (Barthel et al., 2007). Chemokine receptors are comprised of 7-
transmembrane spanning domains, coupled with a G-protein unit for intracellular signal 
transduction (Kufareva et al., 2015). Upon chemokine binding, receptor activation triggers an 
increased flux of intracellular calcium ions (Ca2+), which leads to the exchange of a phosphate 
onto the inactive GDP, to form GTP, cleaving the G-protein subunits, allowing for second 
messenger molecules, such as PIP2, IP3, and DAG to be released and mediate several cellular 
pathways (Lodowski and Palczewski, 2009). These second messengers stimulate both cell 
polarisation, and selectin or integrin expression. Leukocyte polarisation leads to migration 
towards the area of high chemokine concentration, thereby the extravasation of the cell through 
the endothelium towards the area of damage or infection. Once released from the endothelium, 
the cell can act to protect the body. Following their activation, the chemokine receptors are 
often internalised in response to elevated chemokine concentration (Neel et al., 2005). Receptor 
internalisation is a part of the homeostatic control of the inflammatory response. A decreased 
degree of receptor activation due to the reduction of receptor presence, will result in a 
diminishing expression of the chemotactic gradient, leading to the eventual abolishment of 
inflammation at the site of damage, allowing for the commencement of healing processes. 
1.2.ii Chemokines in health and disease 
Chemokines are involved in the recruitment of inflammatory cells and are a critical part of 
physiological function. Chemokines possess a plethora of roles within the body, outside of the 
more obvious inflammation mediatory role (Raman et al., 2011). 
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During infection chemokines exhibit the role of chemoattractant proteins for varying 
inflammatory cells such as T cells and monocytes (Haringman et al., 2003). The 
chemoattraction of these cells leads to the promotion of pathogen clearance, where these cells 
can actively destroy the source of infection and develop immunity against them, thus protecting 
the host from disease. However, several diseases are linked with the disruption of chemokines 
in this role. 
Inflammatory disease and autoimmune disease are prime examples as they are governed by an 
excessive inflammatory response to stimuli. Pathogenesis arises from inflammation-based 
damage and cellular destruction. In several inflammatory diseases including Crohn’s disease 
(CD) and ulcerative colitis (UC), being two forms of inflammatory bowel disease (IBD), the 
activity of several inflammatory cells such as T cells are linked with tissue damage via the 
Figure 1. The role of chemokines in leukocyte extravasation. (1) circulating leukocytes 
interact with chemokine induced selectin expressed on the cell surface. (2) selectin interaction 
allows for GAG associated chemokine-receptor binding on the leukocyte. (3) Chemokine (red) 
activation of receptors allows for the expression of integrins to promote leukocyte adhesion. (4) 
Leukocyte undergoes extravasation through the endothelium, towards high concentrations of 
chemokines. (5) Leukocyte has successfully migrated across the endothelium. 
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potentiation of the inflammatory response (Pallone and Monteleone, 2001).  Several 
chemokines have been identified as being involved in excessive chemotaxis of inflammatory 
cells resulting in tissue damage. CXCL8 has been shown to exhibit upregulation within IBD, 
with a positive correlation to the severity of disease (Keshavarzian et al., 1999). Similarly, 
CCL25 has been shown to promote colonic remodelling in a mouse model, the pathology of 
which was substantially attenuated via chemokine inhibition (Bekker et al., 2015).  
Chemokines are also involved in the angiogenic process, exemplified during the wound healing 
process. Damaged tissue upon remodelling, needs to become re-vascularised as to promote 
growth and survival of the tissue. Several chemokines have been identified for involvement 
within this response, including CCL2 and CCL5 (Stamatovic et al., 2006). Regrettably, cancers 
have developed the ability to modulate the chemokine system as to promote angiogenesis for 
tumour growth, thereby enhancing disease progression. As a cancerous tumour progresses it 
requires an immense blood supply to provide nutrients necessary for growth. The upregulated 
production of chemokines in order to promote angiogenic pathways has been observed across 
several cancers (Sarvaiya et al., 2013). The presence of several chemokines including CXCL2, 
are noted to be potent promoters of tumour-associated angiogenesis, associated with poor 
prognostic outcomes in several cancers including prostate (Keeley et al., 2010). The inhibition 
of CXCR2, therefore a decrease in chemokine-mediated activation was directly shown to inhibit 
tumour-associated angiogenesis in pancreatic cancer (Wente et al., 2006). Similarly, in human 
prostate cancer, a reduction in the production of CXCL8 at the tumour site leads to significantly 
lowered vascularisation and a lowered tumour growth (Sun et al., 2001).  
The chemotactic effects of chemokines are not always specifically pro-inflammatory. During 
the wound healing process, along with the promotion of angiogenesis, chemokines also direct 
the trafficking of structural cells for the remodelling and proliferative stages of wound healing 
(Yates et al., 2009). Therefore, the disruption of chemokine involvement within this process 
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can lead to poor wound healing. CXCR2 has been noted for particular importance, as deletion 
of this receptor, thereby chemokine disruption leads to poor healing including a notable 
reduction in keratinocyte migration for epithelialisation. Similarly, in CXCR3 knockout mice, 
re-epithelialisation and basement membrane remodelling is delayed (Yates et al., 2009). 
Cancers also manipulate the chemokine system in ways that promote its own proliferation and 
invasion. Both melanomas and breast cancers have been identified to overexpress the CXCR4 
receptor and are observed to frequently metastasise and invade utilising the lymphatic system. 
CXCL12 is a chemokine present in abundance in the lymph nodes, which allows the cancer to 
traffic into the system, often leading to cancer progression and death (Itatani et al., 2016). 
Numerous cancers have been indicated to exploit CXCL12/CXCR4 mediated migration, 
including breast, lung, melanoma, ovarian, prostate, and pancreatic (Raman et al., 2011).  
Although certain chemokines are identified as important across several diseases, often the true 
extent of chemokine involvement is extreme, as exemplified by rheumatoid arthritis (RA). RA 
is an autoimmune disease, characterised by excessive transient inflammation against the 
synovium of joints (van de Sande et al., 2011). RA is noted to have progressive phases of 
disease, characterised by inflammation, joint destruction, and invasion of fibrous tissues 
resulting in joint immobility (van de Sande et al., 2011). As reviewed by Szekanecz et al. 
(2010), numerous chemokines have been identified, exhibiting various effects across differing 
stages of disease. CXC-chemokines CXCL1, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, 
CXCL9, CXCL10, CXCL12, CXCL13, and CXCL16 have been detected in sera, synovial 
fluids, and synovial tissues of patients with RA produced by synovial macrophages. Similarly, 
CC chemokines that have been identified in serum and synovia include CCL2, CCL3, CCL5, 
CCL7, CCL8, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, and 
CCL28. XCL1 has also been implicated in the accumulation of T cells in subchondral 
mesenchymal cells of afflicted joints. 
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With clearly extensive involvement of chemokines within the pathogenesis of disease, the 
movement towards targeting chemokines for therapeutic development was a natural 
progression. 
1.3.iii Chemokines as therapeutic targets 
The specific targeting of chemokines is primarily achieved by antibody-based therapeutics, 
whereas non-biological inhibitors are typically used to target chemokine G-protein coupled 
receptors (GPCR) (Lodowski and Palczewski, 2009). This review will concentrate on specific 
targeting of chemokines by antibodies. Antibodies are proteins produced by the immune system 
that specifically recognise, bind, and disable or destroy the target protein (antigen) (Suzuki et 
al., 2015). Antibodies possess a variable ‘Fab’ region which binds to a singular epitope, being 
a small and specific sequence of amino acids (Sela-Culang et al., 2013). Antibodies can block 
the target cell or protein by occluding a substantial portion of the protein surface required for 
function. Binding can result in the agglutination of the antigen or stimulation of a complement 
attack system via the ‘Fc’ region of the antibody, resulting in direct phagocytosis of the bound 
proteins (Sela-Culang et al., 2013).  
The use of antibody-based therapeutics in targeting the inflammatory response has yielded 
successful indications within autoimmune disease. RA is one particular disease in which the 
use of therapeutic antibodies has been investigated, suggesting some degree of success, for 
example the approved TNFα inhibitor Infliximab (Perdiger, 2009). The use of therapeutic 
antibodies against chemokines however has not yielded such advancement, although animal 
models suggest otherwise.  
An antibody against CCL5 was investigated for the treatment of an induced arthritis model in 
rats (Barnes et al., 1998). The antibody indicated both substantial reductions in serum CCL5 
levels, supported by an improved radiological score which considers cartilage loss, joint 
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erosion, and bone ossification. These findings were matched with the use of a systemic anti-
inflammatory as a positive control. Similarly, in another arthritis model in mice, daily injection 
of an anti-CCL2 antibody prevented the onset of arthritis, also exhibiting improvements in joint 
quality when administered during later disease progression (Gong et al., 2007). The prevention 
of macrophage invasion in rat joints in an arthritis model was also observed with administration 
of a CCL2 neutralising antibody, giving a basis for the mechanism of chemokine inhibition for 
disease amelioration (Ogata et al., 1997).  
Based upon animal findings, the use of anti-CCL2 antibodies were assessed for the use in 
patients with RA. A randomised control trial was conducted where anti-CCL2 antibody 
ABN912 was administered via IV on days 1 and 15, of the entire 120-day trial (Haringman et 
al., 2006). Of all the parameters assessed there was no indicated improvement of clinical 
symptoms, nor an indication of a reduced disease activity (indicated by biomarkers). 
Alongside failings in translatability of chemokine-targeting antibody efficacy from animal to 
human models of arthritis, similar discrepancies are found within the use of chemokine 
targeting antibodies in cancers. Loberg et al. (2007) investigated the potential use of antibody 
targeting of CCL2 in a mouse model for treatment against the progression of prostate cancer 
tumours. With systemic administration of anti-CCL2 antibody CNTO888, an average of 42% 
reduction in tumour volume was observed compared to antibody control. The human antibody 
CNTO888 also reduced the average number of vascular sprouts from tumour sections, from 27 
to 1, compared to the antibody control. In a phase II clinical trial conducted by Pienta et al. 
(2013) the potential use of an anti-CCL2 antibody was investigated in metastatic castration-
resistant prostate cancer patients. Regrettably, in this study there was no notable reduction 
observed regarding the metastasis and invasion of the tumour, including no observed increase 
in progression free survival. From analysis of serum samples, a significant reduction in serum 
CCL2 was observed immediately post-dosage, however this reduction was not maintained.  
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As reviewed by Szekanecz and Koch, (2015), antibody-based human trials have had limited 
success, with less than 15% of human trials showing any treatment efficacy, irrespective of the 
significant efficacy observed in animal models. It was suggested a high receptor occupancy is 
required to successfully inhibit the extravasation of inflammatory cells to the joint mediated by 
chemokines. However, with systemic expression of these receptors, reaching a substantial 
amount of chemokine inhibition is unlikely. As there is significant promiscuity in the 
chemokine network, with vast numbers of chemokines performing redundant roles, studies have 
also investigated targeting chemokine receptors to increase the inhibitory potential of the 
therapeutic. However, researchers have struggled to generate antibodies translatable to human 
populations, as may antibodies found to bind chemokine receptor produce no neutralisation 
effect (Dorgham et al., 2016). To date, only one antibody targeting a chemokine receptor 
(CCR4) has been approved for use (Vela et al., 2015). Alternately, small molecule drugs have 
been developed that successfully target and inhibit specific chemokine receptors. However, 
none have shown clinical success for treating inflammation (Pease and Horuk, 2010).  
Although there has been limited success with the development of efficacious therapeutics 
against chemokines, utilising antibodies against chemokines as diagnostic tools may still lead 
to valuable insights within the realm of inflammatory disease. 
1.3.iv Chemokines as diagnostics 
Chemokines have important roles as markers for inflammation, indicators of general 
inflammatory levels, along with providing essential information toward the characterisation of 
migrating inflammatory cells. Chemokine involvement in disease is often determined through 
quantification within sera or biological samples. The development of chemokine-based 
diagnostic markers is ongoing, with several being indicated for dynamic detection and 
characterisation of disease, including within cancers and autoimmune disease.  
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Cancers are known to both overexpress chemokines and chemokine receptors. For prostate 
cancer, the use of prostate specific antigen (PSA) as a biomarker is limited, as the prognostic 
abilities are questionable. Alternately, CCL2 has been identified as a prognostic, potentially 
being more effective towards identifying disease severity in low level PSA patients (Macoska 
et al., 1997; Tsaur et al., 2014). Similarly, the limited sensitivity of viral strain detectors for 
predicting the correlation of human papilloma virus (HPV) infection with cervical lesions and 
cancer development prompted the investigation of chemokines, specifically CCL2, as 
prognostic indicators (Bhatia et al., 2018). In blood samples from lung cancers patients, several 
CXC chemokines were investigated, indicating a correlation between the presence of CXCL4 
and CXCL5 and a greater likelihood of relapse post-surgical intervention (Spaks et al., 2017).  
The use of chemokines as diagnostics is being investigated for diseases such as RA and other 
forms of arthritis. Soluble chemokine concentrations were determined within bone marrow 
samples of RA and osteoarthritis patients in relation to T cell accumulation (Dominguez-Villar 
M and Hafler, 2018). CX3CL1 and CCL5 were identified to be overexpressed, likely 
contributing to T cell accumulation, whereas CCL2, CXCL12, and CXCL1 were not 
(Warnawin et al., 2016). In another study examining the serum samples of RA patients, 
CXCL13 was identified as a positive serum diagnostic for RA compared to healthy controls 
(Allam et al., 2018). Interestingly, there was a higher correlation of expression with patients 
with recently identified RA (< 12 months) compared to patients with established RA. As early 
diagnosis is mandatory for successful intervention, a marker which indicates the establishment 
of disease could be critical for treatment.  
Arguably the most interesting use for the manipulation of chemokines for diagnostic purposes, 
would be the use of in vivo methods of imaging. By utilising the biological role of chemokines, 
the ability to target chemokine receptor expression has been developed. In a study conducted 
by Meincke et al. (2011), conjugates of CXCL12 and a near infra-red (NIR) fluorophore were 
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created and screened for use for CXCR4-expressing MCF-7 breast cancer tumours in mice. 
Optical imaging offered a successful, non-invasive, and sensitive tumour detection method. 
Similarly, CXCR7 is often overexpressed in the tumour microenvironment. The use of a 
radiolabelled antibody against this receptor allowed for the enhanced detection of high CXCR7-
expressing breast, lung, and oesophageal cancer xenografts utilising SPECT imaging 
techniques, suggesting the utility of radiolabelled identification of the chemokine network 
(Behman et al., 2016). However, Nishizawa et al. (2010) found that upon investigation for a 
fluorescently labelled antibody, the antagonist identified both CXCR4 receptors expressed on 
urothelial cancer cells and leukocytes. This suggests a fundamental failure for cancer targeting, 
where there is a loss of specificity due to background detection.  
Although certain chemokines do indicate positive diagnostic ability, targeting singular 
chemokines may limit the discovery of the true extent of chemokine involvement. In situations 
where several chemokines, or a class of chemokines needs be identified, several antibodies 
must be employed. Here, issues can arise when it comes to experimental procedure, often 
requiring entirely separate sample testing for each singular chemokine. A solution for this may 
come from a viral source, specifically, secreted proteins from viruses that bind multiple 
chemokines as a means of defending themselves against the host immune response. 
1.3 Viral Immune Evasion 
Viruses are infectious agents which reproduce within another ‘host’ organism. They infect the 
host, then integrate themselves into biological processes such as gene transcription, producing 
proteins required for viral replication (Walsh et al., 2013). Many organisms have complex 
defence mechanisms against viral infection, such as an adaptive immune system. The immune 
system is able to recognise the invading viral pathogen and destroy it, eliminating the ability 
for the virus to successfully replicate (Walsh et al., 2013). The complexity and intricacy of virus 
propagation in host organisms has stemmed from the co-evolution of viruses alongside their 
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hosts (Sharp and Simmonds, 2011). Where a host evolves new mechanisms to protect against 
viral infection, the virus develops new methods of evasion. There are a range of immune 
evasion strategies viruses employ, with different families of viruses often utilising distinct 
evasion techniques, including antigenic drift, latency, and immune modulation.  
Antigenic drift is a method of immune evasion, famously employed by viruses such as Influenza 
virus (Boni et al., 2009). Antigenic drift is the creation of “immune-escape variants” of the 
virus strain via deliberate mutation of proteins on the virion surface that are recognised and 
targeted by host antibodies. Through regular mutations in these proteins, the host immune 
system may not recognise the “newer” viral strain thereby resulting in the ability of a virus to 
re-infect the host.  
Latency is a method in which a virus successfully replicates within the host and becomes 
permanently integrated within host cells (Nicoll et al., 2012; Mbonye and Karn, 2017). After 
initial infection, the viral genome can become integrated within host cells, being in a reversibly 
inactive state of infection. This allows the virus to persist in the host long after the initial 
“active” infection is cleared. Human immunodeficiency virus (HIV) is the most infamous of 
viruses to employ this tactic for survival, developing genomic reservoirs within individual T 
cells, and constantly producing low levels of infectious virus. Herpes simplex virus-1 employs 
a similar strategy in which the viral genome is maintained in a seemingly inactive state within 
neurons, only emerging when the host is stressed, and the immune system is likely weakened.  
Immune modulation is a method by which a virus can avoid elimination (Engel and Angulo, 
2012; Alcami, 2003). Immune modulation often involves the direct modulation of the host 
immune system, including direct interactions with host cytokines and chemokines. The 
interactions with these host proteins is undertaken by secreted virulence factors. Virulence 
factors are proteins secreted via host cells, after viral integration into host DNA during 
infection. These proteins then subvert the immune response of the host via the direct modulation 
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of the immune response against infection (Engel and Angulo, 2012). These virulence factors 
often mimic, either structurally and/or functionally, host proteins involved in typical immune 
regulation. This secretion of homologous proteins observed by viruses is a result from the virus 
previously capturing host genes, or even evolving its own (Felix and Savvides, 2017).  
There are numerous forms of these virulence factors employed, targeting varying areas of the 
inflammatory cascade in order to subvert and evade host immunity. Known virulence factors 
include; homologues of host cytokines and chemokines, homologues of their receptors, and 
inhibitory binding proteins of which are unrelated structurally to host proteins (Alcami, 2003; 
Felix and Savvides, 2017). Large DNA viruses, including poxvirus and herpesvirus families, 
are almost exclusively the only viral family to produce protein homologues for the purpose of 
immune evasion. These viral homologues are mimics of host proteins, which are utilised to 
block different aspects of the immune response to which the virus is exposed (Alcami, 2003). 
Protein homologues found within these families of viruses include growth factors, cytokines, 
and chemokines. Another class of virulence factors are cytokine and chemokine binding 
proteins (Gonzalez-Motos et al., 2016). These virulence factors can be homologous to known 
host receptors or share no homology to any known host protein (Gonzalez-Motos et al., 2016). 
1.3.i Viral chemokine binding proteins 
Viral chemokine binding proteins (vCBPs) function to act as soluble inhibitory proteins, 
engaging in extensive interactions across several host chemokines, inhibiting the chemokines 
typical biological function. These vCBPs have been identified across a range of viruses, 






Table 2. Secreted viral chemokine binding proteins. 
Virus 
Family 
vCBP Virus Species Binding Site Target(s) Potential therapeutic role 





CC chemokines Asthma 
Wound healing Inflammatory 
skin 





















 M-T7 Myxoma GAG binding 
domain 
C, CC, and CXC 
chemokines 
Transplant vasculopathy 








Herpesvirus M3 MHV-68 GPCR and GAG 
binding domains 
C, CC, CXC, CX3C 
chemokines 
Pancreatitis  
Intimal hyperplasia Inhibition 
of B cell chemotaxis 
Adapted from Lucas and McFadden, (2004); Heidarieh et al. (2015); Gonzalez-Motos et al. (2016). Bovine popular Stomatitis 
virus (BPSV). 
The inhibitory action of the proteins can vary, where vCBPs can mask different parts of the 
chemokine, thereby inhibiting varying protein interactions. Classical inhibition would be 
considered the blocking of the receptor binding site which engages the chemokine receptors, 
thereby blocking the GPCR signalling cascade, and subsequently inhibiting the formation of 
the chemotactic gradient. Alongside this form of inhibition, several of the vCBPs bind to the 
GAG binding domain of the chemokine inhibiting the adhesion and stabilisation of the 
circulating chemokine. Lastly, vCBPs can interact directly with GAGs, thus inhibiting the arrest 
of circulating chemokines through a competitive interaction. 
One of the vCBPs that is conserved amongst Orthopoxviruses is classed as secreted CC 
chemokine binding proteins, called 35 kDa (Lalani et al., 1998). These proteins function to 
competitively inhibit CC binding to cellular receptors, binding the chemokine with high 
affinity.  Binding of the chemokine inhibits the cellular chemokine receptor activation, thus 
inhibiting the increase in calcium concentration required to migration of cells along the 
chemotactic gradient. There are two other 35 kDa-like CBPs that have been discovered, M-T1 
and CBP, which are distinguishable as possessing more extensive roles. M-T1, from Myxoma 
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virus, a Leporipoxvirus, also possesses the unique ability to interact with GAGs, having a 
conserved GAG binding domain (Seet et al., 2001). This interaction could allow for the secreted 
protein to persist in the inflamed area, thus enhancing its inhibitory effect. The vCBP derived 
from Orf virus (ORFV), a Parapoxvirus, known as CBP, has extensive chemokine interactions 
across multiple classes of chemokines (Counago et al., 2015). It has been identified that CBP 
has the ability to bind with high affinity across C, CC, and CXC classes, inhibiting receptor 
activation. There has also been a proposed GAG interaction discovered, however complete 
characterisation is yet to occur. M-T7 from myxoma virus is also a broad range chemokine 
inhibitor of C, CC, and CXC chemokines, however, binding occludes the GAG binding domain 
of the chemokine (Lalani et al., 1997). The A41 vCBP exhibits similarities to the 35 kDa 
vCBPs, being able bind to CC chemokines, but is unable to do this in the presence of GAGs 
(Bahar et al., 2008).  This suggests that the protein both impedes the binding of GAGs to 
chemokine, and also exhibits interactions with GAGs itself. The M3 vCBP from 
Gammaherpesvirus 68 is a unique protein, exhibiting the ability to bind chemokines across all 
chemokine classes (Alexander-Brett and Fremont, 2007).  The M3 protein binds with high 
affinity to prevent both the chemokine-chemokine receptor interaction, and the chemokine-
GAG interaction.  
Interestingly, as vCBPs bind specific chemokines across varying classes, the novelty of 
achieving multiple chemokine inhibition may be achievable. Where antibodies target and 
inhibit singular proteins, vCBPs indicate the ability to bind and inhibit several. 
1.3.ii Viral chemokine binding proteins as therapeutics 
Chemokine targeting is a somewhat novel approach for subverting the inflammatory response, 
having led to the development of a large field of therapeutic investigation. For diseases which 
are intrinsically involved with the overexpression of chemokines, the application of vCBPs 
provides a new scope for therapeutics. The ability to bind several chemokines may provide 
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novel insights to therapeutic development, as the failings of current anti-chemokine 
therapeutics are often based upon the theory of chemokine and receptor redundancy (Szekanecz 
and Koch, (2015).  
One of the most investigated vCBPs for therapeutic development is a 35 kDa vCBP from the 
orthopoxvirus Vaccinia virus; vCCI. This vCBP has been shown to inhibit chemokine-induced 
eosinophil migration in vivo guinea pig skin wound model (Reading et al., 2003).  Similarly, 
vCCI has exhibited anti-eosinophil migration in mouse lungs (Reading et al., 2003). These led 
to the intranasal administration of vCCI in an allergic-asthma mouse model. Treatment 
drastically improved pulmonary and physiological function of the airways, decreasing localised 
inflammation, with no observation of systemic immune-suppression (Dabbagh et al., 2000).  
Several vCBPs have been reported to inhibit the migration of numerous cell types during the 
wound healing and skin inflammation processes. The administration of a vCBP from the 
parapoxvirus Bovine popular stomatitis virus (BPSV), to murine skin stimulated with bacterial 
lipopolysaccharide (LPS) for the initiation of an inflammatory response, indicated a substantial 
reduction in the infiltration of neutrophils and macrophages to the skin. Similarly, in a dermal 
punch model, this vCBP was identified to inhibit wound inflammation in mice in ways which 
mimic the pathogenesis of viral lesions produced during BPSV infection. The genetically 
related CBP indicated a similar effect, where in both an in vitro chemotaxis assay and LPS-
stimulated skin model, a substantial reduction in monocyte recruitment was observed (Lateef 
et al., 2009). In a similar study, the administration of CBP inhibited the chemotaxis of dendritic 
cells (DCs) to inflamed skin, and also from the skin to the draining lymph nodes, thereby 
preventing T cell activation (Lateef et al., 2010). Topical administration of vCCI to skin wounds 
was also shown to inhibit CCL2, CCL5 and NF-kB p65 subunit expression, enhancing 
neovascularisation and wound closure in mice (Ridiandries et al., 2017).  
20 
 
In a murine stroke model, Lee et al. (2015) found that a single administration of the BPSV CBP 
significantly reduced the plasma levels of CCL2 and CXCL2, exhibiting a protective, albeit 
temporary effect against leukocyte infiltration into the brain. Infarct development was delayed 
following treatment, suggesting the use of a vCBP could provide a window of opportunity for 
other therapeutic interventions. 
The herpesvirus M3 vCBP has been shown to inhibit B cell chemotaxis via the inhibition of 
CCL19 and CCL21 (Jensen et al., 2003). This vCBP has also shown efficacy across transgenic 
mice studies for both intimal hyperplasia and pancreas-specific leukocyte infiltration, 
coincidentally being where the virus typically develops latency (Pyo et al., 2004; Jensen et al., 
2003). 
During organ transplantation there is a high incidence of inflammatory responses against the 
grafted tissue, which is responsible for the majority of cardiac graft losses (Miller et al., 2000). 
Both myxoma virus vCBPs, M-T1 and M-T7, have been successfully indicated in animal 
models to attenuate CCL2 based promotion of fibrosis within newly grafted tissue (Liu et al., 
2004; Belperio and Ardehali, 2008).  
Research directed towards the development of therapeutics for inflammatory diseases, utilising 
these viral proteins, highlights key features of the vCBPs which are beneficial and could 
improve upon previous failings. Key features which suggest vCBPs could be successful 
therapeutically include their high affinity, small size, and broad spectrum of inhibition 
(Counago et al., 2015; Lalani et al., 1998; Alexander-Brett and Fremont, 2007; Bahar et al., 
2008). Similarly, with many anti-inflammatory therapeutics, studies utilising vCBPs have 
highlighted common issues with the therapeutic targeting of inflammation. A study conducted 
by Lee et al. (2015) indicated that the BPSV CBP which initially dampened the inflammatory 
response in a stroke model, later potentiated the inflammatory response and increasing infarct 
damage, in a manner similar to reperfusion injury. Similarly, Culley et al. (2006) demonstrated 
21 
 
the inhibition of chemokine mediated inflammatory response via inhibition of CCL5 in an RSV 
model utilising an antibody. However, upon progressing infection a characterised “second 
wave” of CCL5 production was observed, even greater in mice previously treated with the 
antibody against CCL5. These findings further illustrate the complexity of targeting the 
chemokine network, as had previously been demonstrated with failings of human anti-
chemokine therapies. Another potentially serious limitation with therapeutic application of 
CBPs are immunogenic reactions which may limit the time period for which CBPs may be 
utilised, and could further exasperate disease (Baker et al., 2010).  
As the risks associated with CBP use as therapeutics could out-weigh their potential benefits, it 
may therefore be more appropriate to explore their utility in a diagnostic setting. As chemokines 
are being explored as biomarkers for autoimmune diseases and cancer, the use of a high affinity 
broad spectrum viral CBP may have utility in these clinical scenarios fulfilling the role the 
currently played by antibodies.  
1.3.iii Viral chemokine binding proteins as diagnostics 
Viral CBPs have shown utility as chemokine inhibitors, but like antibodies may have their 
issues as therapeutics. Detection of chemokines may be beneficial to diagnose inflammation, 
through the detection of inflammatory chemokines in the blood or tissues, previously via the 
use of antibodies. The use of vCBPs may even offer greater sensitivity than antibodies as 
diagnostics due to their broader chemokine selectivity and high affinity. But no-one to date has 





1.4 Project Objective 
The intention of this study is to investigate the potential utility of a vCBP as a tool for detecting 
inflammatory chemokines in a range of diagnostic platforms. The vCBP chosen for this study 
is derived from the poxvirus, ORFV. This virus causes contagious pustular dermatitis in its host 
(sheep and goats) and also commonly known as orf (disease) when it is transmitted to humans 
(Fleming et al., 2015). Active infection replicates within regenerating epidermal skin cells. 
Infection causes a robust anti-viral immune response characterised by early neutrophil invasion, 
followed by a later influx in a plethora of other leukocytes including T cells and B cells. The 
primary infection typically persists for 4-6 weeks, with the ability to re-infect its host. These 
characteristics of infection have largely been attributed to production of virulence factors by 
the virus, including vascular endothelial growth factor (VEGF) and interleukin (IL)-10 
homologues, a granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-2 
inhibitory factor designated GIF, and CBP. The CBP protein successfully binds and inhibits the 
activity of chemokines across C, CC, and CXC chemokines with high affinity (Seet et al., 2003; 
Lateef et al., 2009; Lateef et al., 2010; Counago et al., 2015). This vCBP has a critical role in 
virus virulence and pathogenesis, as deletion of the CBP encoding gene leads to a substantially 
diminished disease state (Fleming et al., 2017). The vCBP CBP, could offer potential as a 
broad-spectrum chemokine detector to be used in clinical diagnostics based on these 
characteristics.  
1.4.i Hypothesis 
The use of CBP will provide a dynamic tool for the detection of chemokines, with a greater 
sensitivity than antibodies which are specific for singular chemokines. The CBP will be able to 
be employed across both immuno-fluorescent cytology and enzyme-linked immunosorbent 
assay (ELISA) techniques for the detection of chemokines in their native state. The use of CBP 




Aim 1: To develop a fluorescently labelled CBP and assess the resulting impact on protein 
functionality.  
- Develop a protocol for conjugation of a fluorescent label to CBP. 
- To assess the impact fluorescent conjugation to CBP in chemokine binding assays. 
Aim 2: To assess the efficacy of fluorescently labelled CBP in immuno-fluorescent cytology 
protocols. 
- Develop a protocol for an inflammatory assay characterised by inflammatory 
chemokine production.  
- Compare the abilities of fluorescently labelled CBP with a fluorescently labelled 
chemokine-specific antibody to detect inflammatory chemokines in this assay. 
Aim 3: To assess the efficacy of CBP in Western blotting protocols. 
- Compare the abilities of fluorescently labelled CBP with a fluorescently labelled 
chemokine-specific antibody to detect an inflammatory chemokine by western blotting. 
Aim 4: To assess the efficacy of CBP in ELISA protocols. 
- Incorporate CBP into a capture ELISA protocol as a substitute for the capture antibody 
and assess its efficacy. 
- Incorporate CBP into a capture ELISA protocol as a substitute for the detection 





2.1 Protein Production 
2.1.i General reagents 
Dulbecco’s Modified Eagle Medium (DMEM) (pH 7.4) – 1 packet DMEM powder (Gibco 
#12800-017), 3.7g NaHCO3, 4.77g Hepes, 1.5μL β-mercaptoethanol, 1L milliQ H2O filter 
sterilised (0.25μm). 
Dulbecco’s Phosphate Buffered Saline (DPBS) – Dulbecco A PBS tablet (Oxoid Ltd) in 100mL 
milliQ H2O filter sterilised (0.2μm). 
293T Medium – 200mL DMEM containing 20mL foetal calf serum (FCS) (ThermoFisher) 
(heat inactivated at 56oC for 30 minutes), 2mL PSK (100μg/mL penicillin, 100μg/mL 
streptomycin sulphate, 120μg/mL kanamycin sulphate), 400μL hygromycin B 50mg/mL).  
293T Serum Free Medium – 200mL DMEM containing 200mg bovine serum albumin (BSA) 
(Sigma) 2mL PSK. 
Freezing Solution – 90% FCS (heat inactivated), 10% Dimethyl sulfoxide (DMSO) 
(Invitrogen), filter sterilised. 
2.1.ii Cell line 
Human embryonic kidney (HEK)-293T - Transformed HEK-293 cell line stably expressing 
FLAG-tagged ORFV NZ2 CBP from the pAPEX ORFV 112 CBP plasmid (Seet et al., 2003).  
The cell line was stored in liquid nitrogen, then revived through thawing in a 37oC water bath. 
Cells were then transferred into 10mL of 293T media, centrifuged at 300g for 5 minutes, and 
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media was removed leaving pelleted cells. Cells were then re-suspended in 12mL of media and 
transferred into T75cm2 tissue culture flasks for bulking.  
All cells were maintained in T175cm2 tissue culture flasks in applicable medium at 37oC with 
5% CO2.  
For freezing, cells were centrifuged at 300g for 5 minutes, followed by resuspension in freezing 
solution, at a concentration of 1x107 cells per mL. Cells were then aliquoted into 1mL freezing 
tubes and stored in liquid nitrogen. 
2.1.iii Production of CBP 
For protein production, CBP expressing HEK-293T cells were grown until reaching 80% 
confluency, in T175cm2 flasks. Upon desired level of confluency, cells were gently washed 
with warmed DPBS. Fresh, warmed serum free medium was then added, to allow for the protein 
to be produced in the absence of chemokines found within the FCS. Cells were incubated for 3 
days before supernatant was collected and stored at -80oC for later protein purification.  
2.2 Protein Purification and Concentration 
2.2.i General reagents 
Tris-buffered Saline (TBS) (pH 7.4) – 8g NaCl, 0.2g KCl, 3g Tris-base, in 1L milliQ. Adjust 
to pH 7.4 using HCl. 
TBS/T – TBS containing 0.02% Tween 20. 
TBS-G-A – TBS containing 50% glycerol and 0.02% sodium azide. 
5M NaCl – 146.1g NaCl, in 500mL milliQ.  
10X PBS – 80g NaCl, 2g KCl, 11.35g Na2H2PO4, 2g KH2PO4, in 1L milliQ. 
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1X PBS – 100mL 10X PBS, in 900mL milliQ. 
Glycine (pH 3.5) – 3.75g glycine, in 500mL milliQ. 
2.2.ii Anti-FLAG immunoprecipitation 
Cell supernatant containing the FLAG-tagged CBP (200mL) was adjusted for optimal 
purification by the addition of 6mL 5M NaCl, and adjustment of pH to 7.0 using 1M HCl. 
Supernatant was then decanted into four 50mL samples. Gravity flow columns (Biorad) were 
rinsed with 1mL TBS twice followed by the addition of 200μL of Anti-FLAG® M2 affinity gel 
(Sigma), and another TBS wash. Beads were then washed with glycine (room temperature) 
thrice, ensuring glycine is not exposed to beads longer than 20 minutes, followed by five cold 
4oC TBS washes, leaving 1 mL. Remaining beads suspended in TBS were mixed, and 50μL 
was added to each 50mL supernatant sample. Supernatant was rotated with the M2 beads for 2 
hours at room temperature. Supernatant was then centrifuged at 300g or 5 minutes at 4oC, with 
the top 45mL of supernatant removed, and stored at -80oC for later re-immunoprecipitation. 
Remaining supernatant was run through the affinity column, followed by three 1mL TBS/T 
washes, leaving the final TBS-T in the column, which was sealed then rotated for 10 minutes. 
For protein elution, 25μL of FLAG-peptide (Sigma; 5mg/mL) was added with 1mL of TBS/T 
to affinity column, then rotated for 10 minutes. Protein was then eluted for collection, and 
concentration. Each supernatant sample was immunoprecipitated 4X, for protein collection. 
2.2.iii Protein concentration 
Vivaspin (500μL; 10kDa molecular weight cut off) centrifugal concentrators (Sartorius) were 
prepared for the concentration of purified CBP. The concentrators were first dialysed with 
milliQ, then blocked with 500μL 1% BSA in DPBS at room temperature, for 1 hour. 
Concentrators were then washed with 200μL DPBS 3X. Purified protein in TBS/T was then 
added, and centrifuged at 10,000g at 4oC until remaining volume was under 30μL. The protein 
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eluate was then buffer-exchanged, by adding 100μL DPBS to concentrator, and centrifuged 
until the remaining volume was under 30μL twice.  Concentrated protein was stored at -80oC 
for later quantification. 
2.3 Conjugation of Fluorophore 
DyLight®594 NHS Ester fluorophore (ThermoFisher) was added to DPBS. Desired amounts 
of both fluorophore and protein were then combined (total 100μL), vortexed for 5 seconds, and 
incubated for 1 hour (in dark), at room temperature. Fluorophore-labelled protein was added to 
dialysed and pre-blocked concentrators (refer to 2.2.iii) then centrifuged at 10,000g until 50μL 
remained. DPBS was then added to increase the volume to 100μL, which was then spun down 
to 50μL. Remaining protein in DPBS was then carefully removed, and aliquoted for storage at 
-80oC.  
For this research, varying degrees of fluorophore present on CBP was required, utilising varying 
amounts of fluorophore.  For each reaction, 30μL of 0.3mg/mL of CBP was utilised. For 
antibody conjugation, protocol 1 was followed. 
Protocol 1 utilised the highest amount of fluorophore preparation. A needle was added to the 
fluorophore vial, ensuring approximately 3mm coverage. The dye on the needle was then added 
to 80μL of DPBS, with 70μL added to the CBP. 
Protocol 2 utilised an intermediate amount of fluorophore. A 1 in 10 dilution was prepared from 
the fluorophore mix in protocol 1, of which 70μL was added to the CBP.  
Protocol 3 utilised the lowest amount of fluorophore. The fluorophore mix from protocol 1 was 
diluted to 1 in 100 in DPBS, with 70μL added to the CBP.  
Degree of fluorophore conjugation was then determined using the DeNovix DS-11 FX+ 
spectrophotometer and fluorometer. After inputting the extinction coefficient of the protein 
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(obtained via imputing protein amino-acid sequence in ProtParam, via ExPASy), 2μL of 
conjugated protein was placed in the fluorometer. Absorbance was then read at 280nm (for 
protein concentration) and a pre-set 594nm fluorophore absorbance, for quantitation of 
fluorescent conjugation. 
2.4 Protein Analysis 
2.4.i General reagents 
Resolving Buffer (pH 8.8) – 27.23g Tris base, in 150mL milliQ (pH achieved using HCl). 
Stacking Buffer (pH 6.8) – 6g Tris base, in 100mL milliQ (pH achieved using HCl). 
Sample Buffer – 8.4mL 0.05% bromophenol blue, 2mL 0.5M Tris-HCl, pH 6.8, 1.6mL 
glycerol, 3.2mL 10% SDS. 
Reducing Sample Buffer – 1mL sample buffer, 50µL β-mercaptoethanol (2-ME). 
10X Running Buffer – 30g Tris, 144g glycine, 10g SDS, make up to 1L with milliQ. 
10X Transfer Buffer – 25mM Tris, 192M glycine, 20% methanol, make up to 1L with milliQ. 
Wash Buffer – 1L 1X TBS, 2mL 10% Tween 20. 
Blocking Buffer – 20mL wash buffer, 1g skimmed milk powder (Pams). 
Coomassie blue stock – 4mL ortho-phosphoric acid, 20g (NH4)2SO4, 4mL CB-G250 dye 
(Sigma), 192mL milliQ. 
Coomassie blue – 20mL Coomassie blue stock, 5mL methanol. 




Gels were made and run using a Mini-Protean Tetra system from Bio-Rad. SDS-PAGE gels 
were prepared, using the gel mixture outlined in Table 3. Gels were layered, with equal sized 
15% and 10% sections, with 3% utilised for the stacking portion. Protein samples were diluted 
1 in 2 by adding reducing sample buffer, followed by boiling for 15 minutes. Samples were 
loaded with 3µL full-range rainbow marker (Amersham, RPN800E) loaded into the far left 
well. The gels were run at 100V for 2 hours in 1X running buffer.  
Table 3. SDS-PAGE acrylamide gel mixtures. 
 
For protein quantification, both purified protein and a known concentration of carbonic 
anhydrase (CA) were diluted 1 in 2, in sample buffer, boiled for 15 minutes, and loaded onto 
the gel.  Varying volumes of samples were added to SDS-PAGE gels (20, 8, and 3 µL), and 
resolved on the gel.  
2.4.iii Coomassie blue staining 
Proteins resolved by SDS-PAGE gels were stained using Coomassie blue overnight shaking, at 
room temperature. Coomassie blue was then removed, and gels were washed 5X in milliQ, with 
the final wash lasting at least 30 minutes. Gels were then imaged using the BioRad GS-710 
calibrated imaging densitometer.  
 Upper Stacking Gel                    Lower Resolving Gel 
   3% 10% 15% 
Distilled Water 3.25mL 3.47mL 1.8mL 
10% SDS 50µL 100µL 100µL 
50% Glycerol - 200µL 200µL 
Resolving Buffer - 2.5mL 2.5mL 
Stacking Buffer 1.25mL - - 
30% Acrylamide/Bis Solution (BioRad) 0.5mL 3.33mL 5mL 
10% Ammonium Persulphate 30µL 60µL 60µL 
TEMED 15µL 30µL 30µL 
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Coomassie blue stain allowed for the assessment of the protein density of samples. Image J was 
used to find the integrated density of the protein bands, utilising gel background as control. A 
standard curve was obtained using the known concentration and optical density of CA. The 
associated density of the unknown samples was extrapolated against the standard curve, 
allowing for the quantification of the protein density, therefore, the concentration.  
2.4.iv Western blotting 
Sponge pads, blotting papers, nitrocellulose membrane (0.45µm) (Hybond-C Extra; GE 
Healthcare Life Sciences), and (unstained) SDS-Page gel were soaked in cold 1X transfer buffer 
for 15 minutes. After assembly of western transfer apparatus (Bio-Rad), the transfer was run at 
100V for 1 hour in cold 1X transfer buffer.  
For Ponceau S staining, 10mL of Ponceau S was added, and incubated for 5 minutes, at room 
temperature. Membranes were then lightly rinsed with 10mL milliQ 3X, before imaging using 
the BioRad Versadoc MP imager. For fluorescent protein analysis, blots were imaged 
immediately after transfer process had ended. 
For anti-FLAG western blotting nitrocellulose membranes were incubated in blocking buffer, 
overnight, at 4°C. After incubation, nitrocellulose membranes were washed in 10mL wash 
buffer, 3X, for 5 minutes, followed by the addition of anti-FLAG antibody (Table 4) diluted in 
wash buffer. Membranes were then incubated for 2 hours, shaking (in dark), at room 
temperature. After incubation, membranes were washed 3X with 10mL wash buffer, for 5 
minutes. Membranes were then developed using Pierce SuperSignal Chemiluminescent 
substrate for 5 minutes immediately prior to imaging. Developed membranes were imaged 
using the BioRad Versadoc MP imager. 
For western blotting with the labelled CBP and anti-CCL2 antibody (Table 4), nitrocellulose 
membranes containing E. coli expressed recombinant human CCL2 (R&D) were incubated in 
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blocking buffer, overnight, at 4°C. After incubation, nitrocellulose membranes were washed in 
10mL wash buffer, 3X, for 5 minutes, followed by the addition of CBP or antibody diluted in 
wash buffer. Membranes were imaged using the BioRad Versadoc MP imager.  
Table 4. List of the antibodies and proteins utilised across several forms of western blotting 
protocols. 
 
2.5 Enzyme-Linked Immunosorbent Assays (ELISAs) 
2.5.i General reagents 
Coating buffer (pH 6.5) – 1.249g Na2HPO4, 1.547g NaH2PO4, made up to 100mL milliQ, stored 
at 4oC.  
Coating buffer (pH 9.6) – 1.59g Na2CO3, 2.43g NaHCO3, made up to 100mL milliQ, stored at 
4oC.   
Blocking buffer – 100mL 1XPBS, 1g BSA. 
PBS/T – 1L 1X PBS, 5mL 10% Tween 20. 
Stopping solution – 0.16M H2SO4. 
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2.5.ii Direct binding ELISA for determining chemokine/cytokine concentration in 
samples 
A direct binding ELISA technique was used to examine the presence of chemokine or cytokine 
within a sample.  
The ELISA protocol was adapted utilising the BD commercial method for ELISA (BD 
Biosciences, 2019). Maxisorp 96-well flat-bottomed ELISA plates (ThermoFisher) were 
incubated with chemokine or cytokine capture antibody in relevant coating buffer, overnight, 
at 4oC (Table 5). Plates were washed with PBS/T between each step/incubation. Plates were 
then blocked using 100µL of blocking buffer for 1 hour at room temperature.  
Table 5. Cytokine and chemokines used in ELISA protocols, including dilution factor. 
ELISA Kits 













CCL2/MCP-1 Mouse BD #555260 2,000pg/mL pH 6.5 1:100 1:100 
CCL2/MCP-1 Human BD #555179 2,000pg/mL pH 9.6 1:200 1:200 
CCL5/RANTES Human R&D DY478 4,000pg/mL PBS  
(pH 7.4) 
1:200 1:200 
CXCL8/IL-8 Human BD #555244 4,000pg/mL pH 9.6 1:100 1:100 
CXCL2/MIP-2 Mouse R&D DY452 4,000pg/mL PBS  
(pH 7.4) 
1:50 1:25 





CXL1/Lymphotactin Human Individually 
sourced (R&D) 
32,000pg/mL PBS  
(pH 7.4) 
1:50 1:25 




Supernatant samples were then added to the coated plate, incubated for 15 minutes, shaking, at 
37oC.  After incubation, supernatant was removed, and premixed detection antibody and 1 in 
40 dilution of SA-HRP was added to each well, and incubated for 1 hour, at room temperature 
(in dark). Later, TMB substrate was added, followed by incubation in the dark until the colour 
develops. Reaction is stopped using stopping solution. Absorbance of the plate is then read at 
450nm to determine captured chemokine or cytokine concentration.  
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For analysis, a standard curve was created based upon known chemokine concentration. 
Utilising the standard curve, the concentration of chemokine remaining in the samples was 
determined. Data was then presented as chemokine concentration.  
2.5.iii Indirect chemokine binding ELISA as a measure of CBP activity 
An indirect binding ELISA was utilised to examine the binding profile of CBP, specifically the 
ability of CBP to bind soluble chemokine.  
All ELISAs utilised, were based on the R&D commercial method (R&D Systems, 2019). 
Maxisorp 96-well flat-bottomed ELISA pates were incubated with capture antibody, in relevant 
coating buffer, overnight, at 4oC (Table 5). Plates were washed with PBS/T between each 
step/incubation. Plates were then blocked using 100µL of blocking buffer, for 1 hour, at room 
temperature. 
A serial dilution was prepared for the CBP, which was then incubated with relevant chemokine 
standard at the working concentration (Table 5), in a non-absorbent 96-well plate for 45 
minutes, at 37oC, shaking. The CBP-chemokine mix, and a doubling dilution of the chemokine 
standard were then transferred to the coated ELISA plate, and incubated for 15 minutes, 
shaking, at 37oC. Captured chemokine was detected via addition of relevant detection antibody 
conjugated with horseradish peroxidase and incubated for 2 hours, at room temperature (Table 
5). TMB substrate was then added, followed by incubation in the dark for up to 30 minutes, or 
until colour developed. Reaction was stopped using stopping solution. Absorbance of the plate 
is then read at 450nm to determine captured chemokine concentration. 
For analysis, a standard curve was created based upon known chemokine concentration. 
Utilising the standard curve, the concentration of chemokine remaining in the samples was 
determined. Data was then presented as a percentage of unbound chemokine.  
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2.5.iv Indirect binding ELISA, with CBP substituted for the detection antibody 
A modified version of an indirect binding ELISA was designed to examine the potential ability 
of CBP to bind chemokine captured by the pre-coated, capture antibody. In this case, after 
coating and overnight incubation, the standard dilution series and working concentration of 
chemokine was added and incubated for 15 minutes, shaking, at 37oC. A serial dilution series 
of CBP was then added to wells, followed by another 15-minute incubation, shaking, at 37oC. 
ELISA was then continued following the indirect binding ELISA protocol.  
For analysis, a standard curve was created based upon known chemokine concentration. 
Utilising the standard curve, the concentration of chemokine remaining in the samples was 
determined. Data was then presented as a percentage of unbound chemokine.  
2.5.v Direct binding ELISA, with CBP substituted for the capture antibody 
A modified version of a direct binding ELISA was designed to examine the potential ability of 
CBP to be utilised as a substitution for the capture antibody. In this case, wells were coated 
with 1µg/mL of CBP in PBS and incubated overnight, at 4oC. Selected dilution series of 
chemokine standard were added to plates. Protocol after addition of standard is identical with 
the previously described direct binding ELISA protocol.  
For analysis, a standard curve was created based upon known chemokine concentration. 
Utilising the standard curve, the concentration of chemokine remaining in the samples was 




2.6.i General reagents 
Roswell Park Memorial Institute Medium (RPMI) (pH 7.4) – 1 packet RPMI powder (Gibco 
#31800-022) 2.0g NaHCO3, 4.77g Hepes, 1.5μL β-mercaptoethanol, 1L milliQ H2O filter 
sterilised (0.25μm). 
THP-1 Medium – 200mL RPMI containing 20mL FCS (heat inactivated at 56oC for 30 
minutes), 2mL PSK, 2mL 100mM Sodium Pyruvate. 
TBS (pH 7.6) - Tris-buffered Saline (TBS) (pH 7.4) – 8g NaCl, 0.2g KCl, 3g Tris-base, in 1L 
milliQ. Adjust to pH 7.6 using HCl. 
Lipopolysaccharide (LPS) (Escherichia coli 055:B5, Sigma) – LPS diluted in DPBS. 
Phorbol 12-myristate 13-acetate (PMA) (Sigma) – Diluted in DPBS. 
Methanol – 100% methanol, used at -20oC. 
10% Triton X - Triton™ X-100 (Sigma), diluted 1 in 10 in milliQ. 
4’,6-diamidino-2- phenylindole (DAPI) (D3571, Intrivtrogen) - 75 nM, diluted in diluent. 
Diluent – TBS, 1% BSA, 0.5% 10% Triton X. 
2.6.ii Cell line 
THP-1 – Human monocytic cell line derived from an acute monocytic leukaemia patient 
(Bosshart and Heinzelmann, 2016).  
The cell line was stored in liquid nitrogen, then revived through thawing in a 37oC water bath. 
Cells were then transferred into 10mL of THP-1 medium, centrifuged at 300g for 5 minutes, 
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and media was removed leaving pelleted cells. Cells were then re-suspended in 12mL of media, 
and transferred into T75cm2 tissue culture flasks for bulking.  
THP-1 cells were grown in T75cm2 flasks. Upon desired cell concentration, cells were 
centrifuged at 300g for 5 minutes, followed by removal of supernatant.  Pelleted cells were then 
re-suspended in fresh media for assay use.  
For freezing, cells were centrifuged at 300g for 5 minutes, followed by resuspension in freezing 
solution, at a concentration of 1x107 cells per mL. Cells were then aliquoted into 1mL freezing 
tubes and stored in liquid nitrogen. 
2.6.iii Cell stimulation 
Human THP-1 cells, a monocyte cell line, were used for immunofluorescent analysis. Cells 
were seeded at 1x105/mL media cells per well, containing sterile coverslips. Cells were then 
treated with PMA (5ng/ml), or no PMA. After 24 hours, 500µL of media was removed, and 
replaced with either 500µL of media containing 100ng/mL of LPS, or plain media. Cell 
supernatant was collected at 3, 6, and 24 hours post-LPS treatment. Supernatant was centrifuged 
at 300g for 5 minutes to remove cellular debris, and supernatant was stored at -80oC for later 
analysis. Immediately post-supernatant collection, cells were washed with warmed, sterile PBS. 
2.6.iv Cell fixation and permeabilisation 
Cells were then fixed in ice cold, 100% methanol for 10 minutes. Methanol was then removed, 
and remainder allowed to evaporate. PBS was removed and then cells were permeabilised using 
0.1% Triton in PBS, for 10 minutes. After permeabilisation, cells were gently washed with 1mL 
PBS, 3X. Fixed cells were then stored at 4oC until further use.  
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2.6.v Incubation with fluorophore-conjugated anti-CCL2 antibody or CBP 
For staining, 200µL of diluent-diluted antibody or CBP was added to each well, and incubated 
for 2 hours, at room temperature, followed with incubation overnight (in dark), at 4oC. 
After incubation, 100µL of DAPI diluted in diluent was added, and incubated for 30 minutes, 
at room temperature in the dark. After incubation, cells were washed 3X with TBS.  
After staining, coverslips were placed on a 5µL of SlowFade™ Gold Antifade Mountant 
(ThermoFisher), face down, on glass slides. Slides were then stored at 4oC in the dark, for up 
to 3 days. Coverslips were then imaged using 20X magnification on an Eclipse Ni-E upright 
fluorescence microscope and NIS-Elements D Software (Nikon, Tokyo, Japan). 
2.6.vi Competition with fluorophore-conjugated antibody or CBP 
To prevent binding of the labelled antibody or CBP to chemokines within cells, two approaches 
were taken.  
Firstly, cells were pre-incubated with unlabelled antibody or CBP (2µM) 2 hours, at room 
temperature, followed with incubation overnight (in dark), at 4oC.  After incubation, liquid was 
removed, and protocol was continued following the previously outlined method (2.6.v). 
Following washing steps, the labelled antibodies and CBP were added and detected as described 
above. 
Alternatively, the labelled antibody or CBP were pre-incubated with 4-fold molar excess of E. 
coli expressed recombinant human CCL2 (R&D) or heparin sodium salt sourced from porcine 
intestinal mucosa (BioReagent) (heparin) for 5 minutes, shaking at 37oC, in the dark. The 




2.6.vii Quantitation of immunofluorescence 
Replicates of 5 merged images were taken at random per coverslip (1 red (A) + 1 blue (B) per 
technical replicate) (Figure 2). Images were analysed using Fiji, utilising threshold 
measurement, determining the area of staining. Stacked images were analysed separately, 
where the threshold was set, based upon visible comparison between coloured particles. After 
data collation, the area value of fluorescence (red) was divided by the area value of DAPI 
staining (blue). This value was recorded as the relative fluorescence. Replicates of 5 values 
were averaged per coverslip, providing one biological replicate. Three replicates were obtained 
per treatment and presented as a mean relative fluorescence value. Images were presented as a 
layered image (C) of both (A) and (B). 
2.7 Statistical Analysis 
All data within this study was analysed using GraphPad Prism 6. Data was presented as mean 
± SEM.  Based upon the comparison, either T-test, 1-way ANOVA, or a 2-way ANOVA was 
utilised (appropriate test reported in figure legend). If appropriate, and significance was 
achieved, a Bonferonni post-hoc test for multiple comparisons was used. Significance was 


















Figure 2. Immunofluorescent images utilised for Fiji analysis. (A) image representing DAPI 
stain, imaged at 400nm. (B) representing Dylight®594 fluorescence, imaged at 595nm. (C) 




Chemokines are expressed during inflammation, and their detection can be useful 
diagnostically. Viral CBPs exhibit broad chemokine selectivity and high affinity, so may be 
able to detect chemokines in inflamed blood or tissues in a manner similar to diagnostic 
antibodies.  The aim of this thesis was to develop a vCBP as a diagnostic tool and test it in 
situations in which antibodies have shown to be effective.  The vCBP chosen for this work was 
from ORFV strain NZ2, as it is capable of binding across three classes of chemokine with high 
affinity (Counago et al., 2015: Lateef et al., 2009; Lateef et al., 2010). First, CBP was 
conjugated to a fluorescent dye and assessed for potential impact upon CBP function. Secondly, 
labelled CBP was evaluated for its use in direct immuno-fluorescent cytology. Next, labelled 
CBP was evaluated for its use in western blotting protocols. Finally, the native CBP was 
evaluated for its use in ELISAs. 
3.1 CBP in Immunofluorescent Cytology 
For use in cytology CBP needs to be detectable in a system, of which can be achieved through 
conjugation of a fluorescent protein. In this research, the logistics of fluorescent conjugation 
were assessed, specifically its impact on protein functionality. Next, an inflammatory 
immunological assay was developed to directly compare between a labelled antibody and the 
labelled CBP for detection. Several factors were assessed, including the specificity of binding 
to inflamed cells by the antibody and the CBP.  
3.1.i Conjugation of DyLight®594 to CBP 
To aid detection with a fluorescent microscope, a Dylight®594 dye was conjugated onto the 
CBP. A DyLight® dye was chosen as it has successfully been introduced to anti-rabbit IgG 
antibodies previously, and was shown to successfully function as a secondary antibody for the 
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detection and characterisation of CCL2 expression in rat brain sections (Das et al., 2011).  
Analysis of the CBP structure showed that 12 out of 13 primary amine-containing amino acids 
(lysines) on the protein’s surface were peripheral to the previously reported binding site for the 
CC chemokine MCP-1 (CCL2) (Counago et al., 2015; Figure 3).  NHS ester-activation was 
therefore used to conjugate the dye to the surface of the CBP. 
However, labelling of residue K141, or even potentially K241 adjacent to the chemokine 
binding domain could interfere with chemokine binding, so protocols were developed to 
achieve both saturating and sub-saturating levels of dye conjugation. Theoretically, conjugation 
of a saturated level of DyLight®594 to CBP would allow for easiest to detection of the protein 
in fluorescence assays. Whereas conjugation of a minimal level of dye, would be least likely to 
impede on chemokine-CBP interactions. The efficiency and reliability of the Dylight®594 
conjugation protocols were then assessed. 
Prior to dye conjugation with CBP, conjugation protocols were trialled using a test protein, 
BSA. Three protocols were developed in which varying amounts of Dylight®594 dye was 
added (see methods section 2.3). To determine the successfulness of the conjugation protocols, 
the labelled proteins were resolved by SDS-Page under reducing conditions with the abundance 
and fluorescence of the proteins were assessed (Figure 4). Ponceau S staining of the membrane 
revealed bands at the correct molecular weight for BSA (66kDa; Figure 4A).  Also noting that 
Figure 3. Visualisation of lysine residues of the CBP-CCL2 complex. Figure displays all 
primary amine/lysine (blue) residues on the surface of orf virus CBP (red) available for 
conjugation. CBP is complexed with CCL2 (grey), to determine potential impact of fluorescent 
dye conjugation. Figure is rotated 90o around the y-axis, completing a 360o view. Proteins 




equivalent amounts of BSA from each labelling protocol were visualised in lanes loaded with 
equivalent amounts of protein (Figure 4A). The amount of fluorescence associated with the 
BSA also correlated with the amount added into the conjugation reaction, as the highest 
fluorescence was seen with protocol 1, intermediate fluorescence with protocol 2, and barely 
detectable fluorescence with protocol 3 (Figure 4B). There was no visible fluorescence 
observed for the unlabelled BSA (Figure 4B).  
The three conjugation protocols were then used on CBP. The labelled proteins were resolved 
by SDS-Page under reducing conditions, with the abundance and fluorescence of the proteins 
assessed (Figure 5). Coomassie blue staining of the gel revealed bands at molecular weights 
consistent with the CBP monomer (48 kDa) and the CBP dimer (80kDa; Figure 5A).  The 
expected molecular weight for the CBP is however 35 kDa, although glycosylation of the 
Figure 4. DyLight®594 conjugation to bovine serum albumin (BSA).  BSA was conjugated with 
Dylight®594 dye using three different protocols, each using decreasing amounts of dye (1-3). 
Conjugated and non-conjugated proteins, at the amounts indicated, were resolved by SDS-Page 
then transferred to a membrane. (A) Proteins on the membrane were identified by Ponceau S 
staining. (B) Fluorescent dye on the protein was detected by fluorescent imaging using a 610BP 
filter, for fluorescence between 593 and 618 nm. 
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protein has been reported to add up to 25 kDa (Counago et al., 2015).  As the CBP protein was 
engineered with a C-terminal FLAG-tag, proteins were also detected by western blotting with 
an anti-FLAG antibody (Figure 5B); with the size of the bands detected being consistent with 
the monomeric form of the CBP. Equivalent amounts of CBP from each labelling protocol were 
observed with each method, and their sizes appeared equivalent (Figure 5A-B). The amount of 
fluorescence associated with the CBP again correlated with the amount added into the 
conjugation reaction, as the fluorescence was highest with protocol 1, and lowest with protocol 
3 (Figure 5C). Both the monomer and dimer of the CBP were labelled with each protocol. There 
was no visible fluorescence observed for the unlabelled CBP (Figure 5C). 
The number of DyLight®594 molecules conjugated to CBP following each protocol was then 
assessed using fluorescence spectrophotometry. The emission spectrum was adjusted to account 
for the extinction coefficient of CBP; and is presented across equivalent concentrations of 
conjugated and un-conjugated proteins (Figure 6). There was no indication of fluorescence in 
the range of DyLight®594 excitation/emission (593-618 nm) for the unlabelled CBP. This 
process was repeated for at least three batches of CBP, prepared using each of the three 
protocols, thereby obtaining the mean number of DyLight®594 molecules per CBP ± SEM 
(Table 6). Following protocol 1, 10 ± 1.69 DyLight®594 molecules were detected on each 
CBP, although the batch indicating an average of 13.68 was utilised for further testing. This 
indicates complete saturation of the lysine residues was achieved. Following protocol 2, 4.41 ± 
1.26 DyLight®594 molecules were detected on the CBP, although the batch indicating an 
average of 6.42 was utilised for further testing, where approximately half of the lysine residues 
were labelled. Following protocol 3, there were 1.28 ± 0.46 DyLight®594 molecules detected 
per CBP, and a batch reaching 0.89 was utilised for further testing which meant that not every 




Table 6. Reproducablility of the conjugation protocols, for fluorescent conjugation at 
saturating, and subsaturating levels. 
DyLight®594 molecules per CBP molecule 
Conjugation protocol CBP batch 1 CBP batch 2 CBP batch 3 Mean ± SEM 
1 13.68 8.34 8.87 10.30 ± 1.69 
2 6.42 2.10 4.70 4.41 ± 1.26 
3 0.89 0.76 2.20 1.28 ± 0.46 
Figure 5. DyLight®594 conjugation CBP. CBP was conjugated with DyLight®594 dye using 
the three different protocols (1-3). Proteins (300ng per well) were resolved by SDS-Page then 
transferred to a membrane. Proteins were then identified by (A) Coomassie blue staining or by 
(B) Western blot analysis using an anti-FLAG (M2) antibody. (C) Fluorescent dye on the 
protein was detected by fluorescent imaging using a 610BP filter, for fluorescence between 593 





3.1.ii Effect of DyLight®594 conjugation on CBP function 
To examine the binding characteristics of DyLight®594-CBP, indirect chemokine binding 
ELISAs were utilised. This assay measures the loss of soluble chemokine through the 
competitive binding of CBP. It was shown that CBP inhibits, in a dose dependent fashion, the 
ability of the chemokine to be identified through antibody interactions, allowing for a means of 
detecting CBP efficacy (Figure 7).  
This CBP has previously been shown to bind mCCL2 using surface plasmon resonance (SPR) 
(Lateef et al., 2009; Counago et al., 2015). Comparisons between unconjugated and conjugated 
CBP with saturating levels of DyLight®594, indicated there was no significant difference in 
mCCL2 binding, excluding at 2ng/mL (Figure 8A; p > 0.05). The CBPs with mid and low 
Figure 6. Quantitation of DyLight®594 molecules per CBP molecule. DyLight®594-
conjugated CBP prepared using the three different protocols (1-3), and analysed using a 
fluorometer. The absorbance of each protein was taken at increments of 1nm in wavelength. 
The number of dye molecules per molecule of CBP was then calculated using the protein’s 




levels of DyLight®594 conjugation showed no significant differences in mCCL2 binding 
compared to the unconjugated CBP (Figure 8B-C; p > 0.05). The only significant difference 
observed between labelled and unlabelled CBP was a suggested increase in efficacy of the 
labelled CBP. These findings suggest that the extent of dye conjugation does not substantially 
impact the binding characteristics of the CBP.  In addition, the IC50 value for each labelled CBP 
was similar to native CBP, with exception to protocol 3 which indicated a higher affinity 
(1.2nM) (Table 7). Protocol 1 and 2 indicated IC50 values of 1.7 and 1.8 nM respectively, which 
was also similar to the observed affinity of native CBP (1.8nM). 
 
Table 7. Summary of the determined IC50 values of CBP. Table displays the IC50 values (nM) 
of the CBP to chemokine ligands, adjusted to concentration of chemokine used, as determined 
via ELISA. 
Degree of Conjugation 
Chemokine CBP 1 2 3 
mCCL2 1.8 1.7 1.6 1.2 
hCCL2 0.8 1.0   
hCCL5 0.4 0.4   
mCXCL2 1.7 1.8   
hCXCL8 - -   
CBP, 1, 2, and 3 represent conjugation protocol, as outlined in section 2.3. 
1 2 3 4 
Figure 7. Competitive ELISA. Capture antibody (grey) was coated to the ELISA plate (1). 
Varying concentrations of CBP (Dark blue) was incubated with chemokine (red), before 
addition to capture antibody (2). Detection antibody (blue) conjugated with HRP (yellow) was 
then added (3). The presence of detection antibody was then detected by adding TMB 





After establishing that there was no significant difference in CBP binding profile post dye 
saturation, indirect ELISAs were carried out on other chemokines, comparing non-conjugated 
CBP and saturated DyLight®594-CBP only. The chemokines investigated included hXCL1, 
hCCL2, hCCL5, hCXCL4, mCXCL2, and hCXCL8. All chemokines used for investigation 
have previously been shown to bind this CBP (Lateef et al., 2009; Counago et al., 2015; Sharif 
et al., 2016) with the exception of hCXCL8, which was included for use as a negative control.  
Consistent with the binding profile for mCCL2, the DyLight®594-CBP did not substantially 
differ from the unconjugated CBP in its ability to bind hCCL2, the exception being at the lower 
concentrations tested (0.29ng/mL p < 0.05; Figure 9A). A similar profile of chemokine binding 
Figure 8. The extent of DyLight®594 conjugation does not alter CBP binding to mouse 
CCL2.  Various concentrations of conjugated or native CBP were incubated with mouse CCL2. 
Unbound chemokine was then detected using a competition ELISA. (A) The conjugated CBP 
was prepared using protocol 1. (B) The conjugated CBP was prepared using protocol 2 (C) The 
conjugated CBP was prepared using protocol 3. Results are presented as the percentage of 
unbound chemokine, normalised to a CCL2 only control, without the presence of CBP. Values 
are expressed as mean ± SEM (n = 3). The data was analysed using two-way ANOVA, coupled 
with a Bonferonni post-hoc test for multiple comparisons. Significance between groups is 




was observed with hCCL5, where there were no differences in binding between the 
DyLight®594 conjugated and unconjugated forms of CBP, except for below 10 ng/mL (p < 
0.05; Figure 9B). These findings suggest that the DyLight®594-CBP has a higher efficacy for 
chemokine binding. However, calculations of the IC50 for the CBP suggest the unconjugated 
and conjugated CBPs have equivalent binding affinities for both hCCL2 and hCCL5 (Table 7). 
There was no difference found between conjugated and unconjugated CBP in its ability to bind 
mCXCL2 across any concentrations (p < 0.05; Figure 9C). Consistent with previous CBP 
binding studies, dye conjugation did not potentiate any binding with hCXCL8 (p < 0.05; Figure 
10). The binding for CXCL4 was also assessed, however findings failed to successfully indicate 
no binding (Supplementary Figure 1). The binding of XCL1 was also assessed, however no 
binding in the ELISA was shown indicating protocol/manufacture failure (data not included).  
 
Figure 9. Saturation of CBP with DyLight®594 does not prevent binding to human 
chemokines CCL2 and CCL5. Various concentrations of conjugated or native CBP were 
incubated with (A) human CCL2 or (B) human CCL5. Unbound chemokine was then detected 
using a competition ELISA. The conjugated CBP was prepared using protocol 1. Results are 
presented as the percentage of unbound chemokine, normalised to a chemokine only control, 
without the presence of CBP. Values are expressed as mean ± SEM (n = 3). The data was 
analysed using two-way ANOVA coupled with Bonferroni post-hoc test for multiple 




3.2 Development of an in vitro inflammation assay 
Having developed a labelled Dylight®594-CBP, the aim was to use this tool to detect 
inflammatory chemokines in a cell-based inflammatory assay.  The human monocytic cell line 
THP-1 was chosen for this assay, as these cells can express numerous chemokines, including 
CXCL2, CCL5, and CCL2 (Harrison et al., 2005; Higgins and Kovacevic, 2014).  
The first step in setting up this assay was to determine which stimuli induces the greatest 
inflammatory response in these cells. The second step was to determine the time frame of that 
inflammatory response. THP-1 cells were left as monocytes or differentiated into macrophages 
Figure 10. Saturation of CBP with DyLight®594 does not potentiate CXCL8 binding. 
Various concentrations of conjugated or native CBP were incubated with mouse CXCL8. 
Unbound chemokine was then detected using a competition ELISA. The conjugated CBP 
was prepared using protocol 1. Results are presented as the percentage of unbound 
chemokine, normalised to a CXCL8 only control, without the presence of CBP. Values are 
expressed as mean ± SEM (n = 3). 
 
1 2 3 4 
Figure 11. Chemokine detection ELISA. (1) Capture antibody (grey) was coated to the 
ELISA plate. (2) Supernatant samples (containing chemokine) were added to capture 
antibody. (3) Detection antibody (blue) conjugated with HRP (yellow) was added. (4) The 
presence of detection antibody was then detected by adding TMB (substrate), and the OD was 
taken at 450nm. 
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through exposure to PMA for 3 days (Park et al., 2007). The undifferentiated and differentiated 
cells were then treated with or without LPS to stimulate inflammatory cytokine and chemokine 
production. The cell supernatant was then collected across various time points, with cytokine 
and chemokine levels analysed using commercial ELISA kits (Figure 11).  
Firstly, the level of TNFα was examined as to assess the level of inflammation/activation of the 
monocytes. Figure 12A indicates that treatment of THP-1 cells with LPS with or without PMA 
successfully produced an inflammatory response, indicated by the 300pg/mL increase in TNFα 
levels relative to control cells at both 3 and 6 hours post treatment (p < 0.05). The level of TNFα 
however, had substantially reduced for all LPS-treated groups by 24 hours post treatment, no 
longer reaching significance compared with control. PMA-treatment alone led to a 2-fold 
increase in TNFα production at 3 and 6 hours, but this difference was not found to be 
significantly different from the untreated cells (p > 0.05).  
Having shown that the THP-1 cells were producing an inflammatory response to LPS 
stimulation, the timing and level of inflammatory CC chemokines produced by these cells was 
then assessed. The chemokines CCL2 and CCL5 were chosen, as CBP exhibits high affinity 
binding for them (Counago et al., 2015; Sharif et al., 2016). Figure 12B shows that treatment 
of THP-1 cells with LPS, with or without PMA, successfully induced production of CCL2, with 
a significant 8 to 10-fold increase relative to the control cells at 24 hours post treatment (p < 
0.05). PMA-treatment alone did not increase CCL2 production (p > 0.05). Figure 12C shows 
that treatment of THP-1 cells with LPS, with or without PMA, also induced production of 
CCL5, with significant 1.4 and 1.8-fold increases relative to the control cells at 6 and 24 hours 
post treatment, respectively (p < 0.05). PMA-treatment did not increase CCL5 production (p > 
0.05). TNFα, CCL2, and CCL5 expression levels correlate with previous findings utilising LPS 




Figure 12. (A) Tumour necrosis factor (TNFα) production by human THP-1 monocytes 
increased 3-6 hours after treatment with lipopolysaccharide (LPS) with and without phorbol-
12-myristate-13-acetate (PMA). (B) Human CCL2 concentration was increased response to 
LPS exposure. (C) Human CCL5 concentration was increased in response to LPS treatment.  
THP-1 cells were treated with or without PMA for 3 days (5 ng/mL), then treated with or 
without LPS (100 ng/mL) for the indicated time frame. TNFα, CCL2, and CCL5 proteins, 
secreted in cell supernatant was quantified by ELISA with values expressed as the mean ± SEM 
(n = 3). The data was analysed using two-way ANOVA coupled with Bonferroni post-hoc test 
for multiple comparisons. Significance denoted by an asterisk. 
51 
 
3.2.i Conjugation of DyLight®594 to an anti-CCL2 antibody 
Before using the Dylight®594-CBP to detect chemokines expressed by THP-1 cells, a 
chemokine-specific antibody needed to be labelled with Dylight®594 to allow for appropriate 
comparisons between CBP and antibody sensitivity and specificity. As the THP-1 cells 
produced greater levels of CCL2 than CCL5 in response to LPS, compared to non-LPS treated 
cells, an anti-CCL2 antibody was chosen to provide comparison with the DyLight®-CBP. The 
antibody selected (monoclonal, mouse IgG1) had previously been shown to detect hCCL2 in 
immunofluorescent cytology and immunohistochemistry protocols using macrophages isolated 
from RA patients and healthy patients and hepatic tissue from Simian immunomodulatory virus 
(SIV) infected macaques (Rhys et al., 2018; Fisher et al., 2018).  
Conjugation protocol 1 was utilised to label the anti-CCL2 antibody. The labelled antibody was 
resolved by SDS-Page under reducing conditions, with the abundance and fluorescence of the 
antibody assessed (Figure 13B). Coomassie blue staining of the gel revealed bands at molecular 
weights consistent with the IgG1 structure, consisting of two heavy-chains (52 kDa each) and 
two light-chains (26-29kDa each; Figure 13A).  The presence of two distinct bands at 26 and 
29 kDa indicates some variance in light chain size.  
The number of DyLight®594 molecules conjugated to anti-CCL2 antibody was then assessed 
using fluorescence spectroscopy. The emission spectrum was adjusted to account for the 
antibody’s extinction coefficient; and is presented for equivalent amounts of conjugated CBP 
and anti-CCL2 antibody (Figure 14). The mean number of DyLight®594 molecules per 
antibody was determined to be 15.3. A typical mouse IgG1 antibody consists of 16 lysine 
residues (Nagaoka and Akaike, 2003), indicating full saturation. As DyLight® dyes have been 
successfully conjugated to antibodies without loss of function previously (Cilliers et al., 2017) 




Figure 13. DyLight®594 conjugation to anti-CCL2 antibody. Anti-CCL2 antibody was 
conjugated with Dylight®594 dye using protocol 1. Varying amounts of anti-CCL2 antibody 
was resolved by SDS-Page then transferred to a membrane. Proteins were then identified by 
(A) Coomassie blue staining or by (B) Fluorescent dye on the protein was detected by 
fluorescent imaging using a 610BP filter, for fluorescence between 593 and 618 nm. 
Figure 14. Quantitation of DyLight®594 molecules per molecule of anti-CCL2 antibody 
relative to that of CBP. Dylight®594-conjugated Anti-CCL2 antibody and CBP were prepared 
using protocol 1, and analysed using a fluorometer. The absorbance of each protein was taken 
at increments of 1nm in wavelength. The number of dye molecules per molecule of protein was 




3.2.ii Sensitivity of DyLight®594-CBP Binding to THP-1 Cells 
Having prepared DyLight®594 conjugated CBP and anti-CCL2 antibody, it was now possible 
to directly compare their ability to detect chemokine(s) produced by activated THP-1 cells. As 
CCL2 was detected in the supernatant of LPS and PMA-treated cells, this stimulation protocol 
was chosen for the assay. As maximal levels of CCL2 in the supernatant was achieved by 24 
hours, the time point of 6 hours was chosen as it was anticipated the level of intracellular 
chemokine would be at its highest prior to this peak in secretion. 
THP-1 cells grown on coverslips with PMA for 3 days prior to treatment with LPS for 6 hours 
were fixed and permeabilised. The cells were then incubated with a dilution series of equimolar 
amounts of the DyLight®594 conjugated CBP and anti-CCL2 antibody. With the degree of 
fluorescent conjugation near equivalent, it was assumed that equal degrees of binding would 
produce equivalent levels of fluorescence. However, with CBP having a higher affinity and 
more ligands available, there would likely be a greater detection of fluorescence observed.  
Figure 15A illustrates that a dose dependent increase in the fluorescence intensity was observed 
with both the DyLight®594-CBP and the DyLight®594-anti-CCL2 antibody. However, the 
antibody exhibited increased assay sensitivity (increased fluorescence) compared to the CBP.  
The localisation of Dylight®594 conjugated anti-CCL2 antibody and CBP was examined. 
Assuming both proteins are binding chemokines, the proteins should exhibit similar binding 
patterns. As the cells are permeabilised, binding should also be observed within the cells for 
both proteins. Observations on the localisation of protein binding of both CBP and anti-CCL2 
antibody did not appear different (Figure 16). Binding was observed both within the cell, and 
externally. Both CBP and anti-CCL2 antibody indicate a high level of surface fluorescence, 











Figure 15. Dylight®594-anti-CCL2 antibody displayed a higher sensitivity for detection, 
compared to Dylight®594-CBP, across LPS + PMA activated cells. THP-1 cells were treated 
with PMA for 3 days (5 ng/mL), then stimulated with LPS (100 ng/mL) for 6 hours. Cell were 
fixed and permeabilised cells, followed by incubation with varying concentrations of 
DyLight®594-conjugated anti-CCL2 antibody or CBP (molar equivalent) (red) and counter-
stained with DAPI (blue). (A) Representative fluorescent images are shown of cells treated for 
6 hours. (B) Data expressed as Relative fluorescence, being a measure of fluorescence relative 
to DAPI staining. Values are expressed as the mean ± SEM (n = 3). The data was analysed 
using two-way ANOVA coupled with Bonferroni post-hoc test for multiple comparisons.  





Figure 16. The localisation of Dylight®594 conjugated CBP and anti-CCL2 antibody does 
not appear different. THP-1 cells were treated with PMA for 3 days (5 ng/mL), then stimulated 
with LPS (100 ng/mL) for 6 hours. Cell were fixed and permeabilised cells, followed by 
incubation with DyLight®594-conjugated anti-CCL2 antibody or CBP (550nm) and counter-
stained with DAPI. Scale bar is as indicated. (A) image representing DAPI stain, imaged at 
400nm. (B) representing Dylight®594 fluorescence, imaged at 595nm. (C) represents a merged 



















3.2.iii Specificity of DyLight®594-CBP for Activated THP-1 Cells 
Having shown DyLight®594 conjugated CBP and anti-CCL2 antibody could bind activated 
THP-1 cells, it was then important to show that the staining was specific to chemokines. As 
CCL2 production levels varied between untreated, PMA, LPS, and LPS and PMA-treated THP-
1 cells, an assay was conducted to examine the relative level of DyLight®594 conjugated CBP 
and anti-CCL2 antibody following these different cell treatments.  
THP-1 cells grown on coverslips, treated with PMA and/or LPS for 3 to 24 hours, were fixed 
and permeabilised. The cells were then incubated with DyLight®594 conjugated CBP or anti-
CCL2 antibody. A molar equivalent concentration of 550nM was chosen based in the 
significant increase in staining detected in the previous assay (Figure 15).  
The relative fluorescence of DyLight®594 anti-CCL2 antibody was significantly greater in 
cells treated with LPS, with or without PMA, at 6 and 24 hours (p < 0.05; Figure 17A, B). The 
maximal level of fluorescence was achieved with the DyLight®594-anti-CCL2 antibody was 
with cells treated with LPS at 24 hours (Figure 17B), reaching a relative fluorescence of 2, 
compared to 1.1 reached by no treatment.  
The maximal level of fluorescence achieved with the DyLight®594-CBP, was observed with 
cells treated with LPS and PMA at 24 hours (Figure 17A, C), reaching a relative fluorescent 
level of 1.3 compared to 0.75 of untreated control, although not significant. The relative 
fluorescence of DyLight®594-CBP was however not significantly greater in any treated cells, 
compared with untreated cells (p < 0.05; Figure 17C). At 3 hours, there were no significant 
differences between groups, although no treatment did indicate the lowest level of fluorescence 
(Figure 17A). These findings indicate that while the fluorescently-labelled antibody can 
specifically detect activated THP-1 monocytes, the CBP failed to differentiate between cells 













Figure 17. Selective staining of activated THP-1 monocytes with DyLight®594-anti-CCL2 
antibody but not DyLight®594-CBP. THP-1 cells were treated with or without PMA for 3 days 
(5 ng/mL), then treated with or without LPS (100 ng/mL) for the indicated time frame. Cells 
were fixed and permeabilised, followed by incubation with 550nM of DyLight®594-
conjugated anti-CCL2 antibody or CBP (red) (molar equivalent) and counter-stained with 
DAPI (blue). (A). Representative fluorescent images are shown of cells treated for 6 hours. 
Scale bar is as indicated. Mean relative fluorescence was calculated for each treatment, and 
displayed for (B) DyLight®594-conjugated anti-CCL2 antibody or (C) DyLight®594-
conjugated CBP, being a measure of fluorescence relative to DAPI staining. Values are 
expressed as the mean ± SEM (n = 3). The data was analysed using two-way ANOVA coupled 
with Bonferroni post-hoc test for multiple comparisons.  Significance between groups denoted 
by an asterisk. 
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3.2.iv Specificity of DyLight®594-CBP for Chemokines Produced by Activated THP-1 
cells 
Although DyLight®594 conjugated CBP could bind activated THP-1 cells, it was unable to 
differentiate between activated cells producing chemokines, and non-activated cells. This 
suggests that CBP binding to the cells may not be chemokine-specific. A series of competitive 
binding assays were conducted to look at the specificity of DyLight®594 conjugated CBP and 
anti-CCL2 antibody interactions with activated THP-1 monocytes.  
LPS and PMA-activated THP-1 cells were incubated with a 4-fold molar excess of unlabelled 
anti-CCL2 antibody prior to incubation with the DyLight®594 conjugated CBP and anti-CCL2 
antibody (1/100 dilution) (Figure 18). Pre-incubation with the unlabelled antibody is expected 
to block any specific interactions between the fluorescently-labelled antibody or CBP, and 
CCL2 within the cells. The unlabelled antibody clearly reduced the level of fluorescence 
relative to the DyLight®594-anti-CCL2 antibody alone (Figure 18B). However, pre-incubation 
with the antibody had no impact on fluorescence observed with the DyLight®594-CBP. The 
relative fluorescence of the DyLight®594-CBP staining did not differ with or without 
competition from the unlabelled antibody (p > 0.05; Figure 18C).  
Next, activated THP-1 cells were incubated with a 4-fold molar excess of unlabelled CBP prior 
to incubation with the DyLight®594 conjugated CBP and anti-CCL2 antibody (550nM). Pre-
incubation with the CBP is expected to block any specific interactions between the 
fluorescently-labelled antibody or CBP, and chemokines in general within the cells.  The 
unlabelled CBP had no impact on fluorescence after binding with either the DyLight®594-
conjugated anti-CCL2 antibody or CBP.  Quantitative analysis confirmed that the relative 
fluorescence of DyLight®594-CBP and DyLight®594 anti-CCL2 antibody staining did not 






Figure 18. Dylight®594-anti-CCL2 antibody indicates specificity for CCL2, whereas 
DyLight®594-CBP does not. THP-1 cells were treated with PMA for 3 days (5 ng/mL), then 
stimulated with LPS (100 ng/mL) for 6 hours. Fixed and permeabilised cells were then 
incubated with 2.2µM of anti-CCL2 antibody or CBP overnight, followed by incubation with 
550nM of DyLight®594-conjugated anti-CCL2 antibody or CBP (red), and counter-stained 
with DAPI (blue). (A) Representative fluorescent images are shown of cells treated for 6 hours. 
Scale bar is as indicated. Relative fluorescence was calculated for each treatment, and displayed 
for (B) DyLight®594-conjugated anti-CCL2 antibody or (C) DyLight®594-conjugated CBP, 
being a measure of fluorescence relative to DAPI staining. Values are expressed as the mean ± 
SEM (n = 3). The data was analysed using two-way ANOVA coupled with Bonferroni post-
hoc test for multiple comparisons.  Significance between groups denoted by an asterisk. 
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Next, DyLight®594-CBP and DyLight®594-anti-CCL2 antibody were incubated with a 4-fold 
molar excess of CCL2 prior to the incubation with activated THP-1 monocytes (Figure 19). 
Pre-incubation of the fluorescently-labelled antibody or CBP, with CCL2, is expected to block 
any specific interactions with CCL2 within the cells. The CCL2 clearly reduced the level of 
fluorescence relative to the DyLight®594 anti-CCL2 antibody alone (Figure 19A-B). However, 
pre-incubation with CCL2 did not alter fluorescence with the DyLight®594 CBP. The relative 
fluorescence of the DyLight®594-CBP staining did not differ with or without with hCCL2 pre-
incubation (p > 0.05; Figure 19C). Alternately, a significant 18% reduction in relative 
fluorescence by the DyLight®594 anti-CCL2 antibody (1.7 to 1.4 respectively) was observed 
following competitive binding with the CCL2 (p < 0.05; Figure 19B).  
Next, DyLight®594-CBP and DyLight®594-anti-CCL2 antibody were incubated with a 4-fold 
molar excess of heparin prior to the incubation with activated THP-1 monocytes (Figure 20). 
Pre-incubation of the fluorescently-labelled antibody or CBP, with heparin, should not impede 
on either the anti-CCL2 antibody, nor the CBP, of which neither have been indicated to 
successfully bind heparin. The addition of heparin clearly reduced the level of fluorescence 
relative to the DyLight®594-CBP alone, however did not alter fluorescence with the 
DyLight®594 anti-CCL2 antibody (Figure 20A). Quantitative analysis confirmed there was a 
significant 35% reduction in relative fluorescence with the DyLight®594 CBP staining when 
pre-incubated with the heparin (1.7 to 1.1 respectively) (p < 0.05; Figure 20C). DyLight®594 
anti-CCL2 antibody was not altered with competitive heparin binding (p < 0.05; Figure 20B).  
Together, the data indicates that the fluorescently-labelled CBP is unable to specifically detect 
chemokines in fixed and permeabilised cells, suggesting that the fluorescence detected may in 





Figure 19. Dylight®594-anti-CCL2 antibody indicates specificity for CCL2, whereas 
Dylight®594-CBP does not. THP-1 cells were treated with PMA for 3 days (5 ng/mL), then 
stimulated with LPS (100 ng/mL) for 6 hours. DyLight®594-conjugated anti-CCL2 antibody 
and CBP were incubated with 2.2µM CCL2. Fixed and permeabilised cells were then incubated 
with a 550nM of DyLight®594-conjugated anti-CCL2 antibody or CBP (red) with or without 
CCL2 incubation, and counter-stained with DAPI (blue). (A) Representative fluorescent images 
are shown of cells treated for 6 hours. Scale bar is as indicated. Relative fluorescence was 
calculated for each treatment, and displayed for (B) DyLight®594-conjugated anti-CCL2 
antibody or (C) DyLight®594-conjugated CBP, being a measure of fluorescence relative to 
DAPI staining. Values are expressed as the mean ± SEM (n = 3). The data was analysed using 
two-way ANOVA coupled with Bonferroni post-hoc test for multiple comparisons.  









Figure 20. DyLight®594-CBP may indicate specificity for heparin, as opposed to CCL2. 
THP-1 cells were treated with PMA for 3 days (5 ng/mL), then stimulated with LPS (100 
ng/mL) for 6 hours. DyLight®594-conjugated anti-CCL2 antibody and CBP were incubated 
with 2.2µM heparin. Fixed and permeabilised cells were then incubated with a 550nM of 
DyLight®594-conjugated anti-CCL2 antibody or CBP (red) with or without heparin 
incubation, and counter-stained with DAPI (blue). (A). Representative fluorescent images are 
shown of cells treated for 6 hours. Scale bar is as indicated. Relative fluorescence was calculated 
for each treatment, and displayed for (B) DyLight®594-conjugated anti-CCL2 antibody or (C) 
DyLight®594-conjugated CBP, being a measure of fluorescence relative to DAPI staining. 
Values are expressed as the mean ± SEM (n = 3). The data was analysed using two-way 
ANOVA coupled with Bonferroni post-hoc test for multiple comparisons.  Significance 
between groups denoted by an asterisk. 
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3.3 CBP in Western Blotting 
The use of vCBPs was then considered for the use of chemokine detecting within a western 
blot. Typically, after running a protein on a gel and transferring the protein to a membrane, an 
antibody is utilised to detect the protein on the membrane. Visualisation is then achieved 
through either an enzymatic conjugation/substrate interaction, or the use of a fluorescent 
antibody. Utilising CBP as a substitute would likely fail, as extensive protein interactions are 
required to facilitate chemokine binding. The protocol involves the reduction of the chemokine, 
through the disruption of disulphide bonds, therefore the chemokine loses its tertiary structure, 
rendering CBP-chemokine binding unlikely (Homma et al., 2004; Counago et al., 2015). 
The fluorescent labelled antibody was identified to exhibit CCL2 detection across multiple 
concentrations of anti-CCL2 antibody (Figure 21). However, in no instance was binding 
observed for the labelled CBP across any concentration assessed. 
  
Figure 21. DyLight®594-CBP was not able to detect hCCL2 within a western blot protocol. 
Equal amounts of hCCL2 (300ng per well) were resolved by SDS-PAGE gel then transferred 
to a membrane. Membranes were then incubated with varying concentrations of either 
Dylight®594 conjugated CCP or anti-CCL2 antibody. Only the highest concentration (275nM) 
of Dylight®594-CBP was shown. Fluorescence was detected by imaging using a 610BP filter, 
for fluorescence between 593 and 618 nm. 
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3.4 CBP in ELISA 
The use of vCBPs were then considered for integration into various ELISA techniques by 
supplanting the use of antibodies.  The use of native CBP was assessed for use as the detection 
antibody. The vCBP was introduced into the system after the chemokine ligand had been 
captured by the antibody, as outlined in Figure 22. It was hypothesised that the utilisation of 
CBP as a detection antibody would not be successful, as the formation of a capture antibody-
chemokine-CBP complex was unlikely to be facilitated. The formation of this complex would 
be unable to form, either as the CBP has likely occluded the antibody epitope, or CBP has 
competitively removed the chemokine from the capture antibody. 
The data indicates that there is a dose response trend occurring, where at the two highest 
concentrations of CBP there is reduced detection of unbound CCL2 (70% and 83%; Figure 23). 
There were no significant differences observed across the lower dose range. Complete 
inhibition of CCL2 detection was not observed which indicates that CBP cannot fully out-
compete the detection antibody. 
The use of CBP was also assessed as a potential capture antibody substitute, as outlined in 
Figure 24. It was hypothesised that, based upon previous indications of CBP maintaining 
functionality after charge-based adhesion in SPR, ELISA plates coated with CBP would be able 
to bind soluble chemokine (Counago et al., 2015; Sharif et al., 2016). Upon further 
Figure 22. CBP as a replacement detection antibody for hCCL2. (1) Capture antibody (grey) 
was coated to the ELISA plate. (2) Chemokine was added to capture antibody. (3) CBP was 
incubated with pre-bound CCL2. (4) Detection antibody (blue) conjugated with HRP (yellow) 
was added. (5) The presence of detection antibody was then detected by adding TMB 




investigation, there were linear concentration/detection relationships observed (Figure 25). This 
indicated that CBP was successfully capturing the chemokine, also allowing for the access of 
the detection antibody to the ligand, thereby achieving detection in the ELISA. The R2 values 
were calculated as a means for assessing the linearity of the relationship. The mean value was 
0.942 ± 0.029, indicating the data expressed a linear dose/response relationship (Table 8). 
 
  
Figure 23. At high concentrations of CBP, the detection of chemokines via the detection 
antibody was reduced. Various concentrations of native CBP were incubated with human 
CCL2 pre-captured on the capture antibody. Unbound chemokine was then detected using a 
competition ELISA. Results are presented as the percentage of unbound chemokine, normalised 
to a CCL2 only control, without the presence of CBP. Values are expressed as mean ± SEM (n 
= 3). The data was analysed using one-way ANOVA coupled with Bonferroni post-hoc test for 
multiple comparisons. Differences between concentrations were compared to a CCL2 control, 
set at 100%. Significance between groups denoted by an asterisk. 
 
Figure 24. CBP as a capture antibody substitute for human CCL2. (1) CBP (dark blue) was 
coated to the ELISA plate. (2) A standard concentration of chemokine (red) was then added to 
the CBP. (3) Detection antibody (blue) conjugated with HRP (yellow) was added. (4) The 
presence of detection antibody was then detected by adding TMB (substrate), and the OD was 




Table 8. The linear trends observed utilising CBP as a capture antibody. 
  
CBP based standard curve 
 Replicate 1 Replicate 2 Replicate 3 Mean ± SEM 
R2 value 0.8852 0.9822 0.9586 0.942 ± 0.029 
Figure 25. A linear relationship was observed utilising CBP as a capture antibody substitute. 
CBP was coated to the ELISA plate. A dilution series of human CCL2 was then added, and 
chemokine was then detected. Results are presented as the percentage of unbound chemokine, 
normalised to a CCL2 only control, without the presence of CBP. Values are expressed as mean 




Chemokines are increasingly being implicated in the pathogenesis of more and more diseases. 
With developing elucidation of chemokine involvement comes the potential for use of 
chemokines as diagnostic markers for these diseases. Viral CBPs provide novel qualities 
towards the detection of chemokines, exhibiting the unique ability to bind to multiple 
chemokine ligands across different classes. Using the vCBP derived from ORFV strain NZ2, 
CBP, this study aimed to investigate the potential application of vCBPs as broad-spectrum 
chemokine detectors. Specifically, CBP conjugated with a fluorescent dye was investigated for 
efficacy in immuno-fluorescent cytometry and western blotting, whilst the utility of the native 
protein was examined for utilisation in ELISA protocols.  
4.1 CBP and its Utility in Immunofluorescent Cytology 
As to trial the use of CBP in cytometry assays, a protocol was developed to enable different 
levels of conjugation of fluorescent dye onto CBP. The protocol established was rather 
consistent with the addition of a saturating level of the fluorescent dye, whereas the protocols 
for generating sub-saturating levels of dye conjugation were far more variable. Usefully, when 
the desired level of conjugation was not achieved utilising the outlined protocol, the proteins 
could undergo multiple rounds of conjugation to achieve the desired level of conjugation. By 
increasing the scale of the reaction, improvements towards the consistency of the conjugation 
protocols could be made.  As the protocol developed relies on a subjective measurement of dye, 
with greater batches requiring more dye, it would be easier to control the dye to protein-
concentration ratio (associated with lysine residues), allowing for accurate replicability. 
The CBP-chemokine interaction is heavily dependent on charge-based interactions (Counago 
et al., 2015; Seet et al., 2003). There are largely negative and hydrophobic regions of CBP 
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essential for ligand engagement specifically localised on β-sheet II (Counago et al., 2015). 
There are extensive interactions with the chemokine ligands at this site, which result in a high 
affinity for most chemokines (Counago et al., 2015). It is understood that the CBP-chemokine 
interaction occludes the GPCR domain of the bound chemokine, thereby inhibiting receptor 
activation (Counago et al., 2015). This finding is supported by the dose dependent inhibition of 
CCL2 induced monocyte chemotaxis via CBP, as shown in a migration assay (Lateef et al., 
2009). There are notable key residues for GAG binding of the chemokine which are engulfed 
by CBP when complexed (Counago et al., 2015). Theoretically, this may also lead to inhibition 
of the chemokine-GAG interaction, although currently only indicated as a putative interaction 
(Counago et al., 2015). Antibodies by contrast, engage a much smaller epitope of the 
chemokine, also with high affinity. For example, an anti-CCL2 antibody shown to interact with 
residues 18-24 and 45-51, binds human CCL2 with high affinity (0.022 nM, obtained via SPR) 
and inhibits CCL2 binding to its receptor (Obmolova et al., 2012).  
Structural analysis of CBP specifically highlighting the lysine residues was critical, as to 
understand the potential impact of conjugation on chemokine binding. The conjugation protocol 
utilises free primary amine residues, which are exclusively present on lysine residues (Nanna 
et al., 2017). The amine residue is characteristically a positive charge, and it is understood that 
the conjugation of an ester onto the protein, including in the form of a dye, will reduce the net 
charge of the conjugated residue (Nanna et al., 2017). The alteration in charge is a commonly 
investigated feature of antibody conjugation as it can alter the stability, pharmacokinetics, and 
pharmacodynamics of a therapeutic (Nanna et al., 2017). The binding face of CBP required for 
interaction with the chemokine is largely negative, and there are no lysine residues located close 
to this site (Counago et al., 2015). However, there is still the potential for conjugation of the 
fluorophore to alter efficacy of the protein, as lysine residues are located within the CBP dimer 
interface (Counago et al., 2015). Based upon a net charge theory, the lower the extent of lysine 
neutralisation by fluorophore conjugation, the lesser likelihood of the binding characteristics of 
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CBP being impacted. Varying degrees of fluorescent conjugation were completed as a method 
to determine any impact upon chemokine binding activity. Based on the localisation of the 
lysine residues within the CBP, it was hypothesised that fluorescent conjugation would have 
minimal impact on the functionality of CBP. Supporting this hypothesis, it was shown that 
fluorescent conjugation, at any degree, did not substantially impact upon the ability of CBP to 
bind selected chemokines. No noticeable impact was observed following dye conjugation of 
CBP, at any degree, when binding several CC and CXC chemokine ligands (mCCL2, hCCL2, 
hCCL5, and mCXCL2). In addition, the presence of fluorophore conjugation did not facilitate 
the binding of CBP to CXCL8, for which binding is not typically exhibited (Counago et al., 
2015; Seet et al., 2003). A protein labelled with the largest amount of dye possible with no 
detriment towards protein function, would provide an easily detectable and highly sensitive tool 
(Pretzer and Wiktorowicz, 2008). For this reason, this study proceeded with the CBP conjugated 
with saturating levels of the fluorophore. 
The full impact of fluorescent conjugation on the activity of the CBP however, was not 
completely addressed within this study. The binding sites for CBP across chemokine class and 
species has been shown in crystal structures and homology models to vary to some extent 
(Counago et al., 2015). In addition, the interactions between CBP and many chemokines have 
yet to be characterised. Thereby, conjugation to the lysine residues may be more critical for the 
formation of charge-based interactions with specific chemokines. Attempts were made to 
compare the binding ability of the conjugated and unconjugated CBP towards CXCL4, and 
XCL1. However, here the indirect ELISA failed to detect inhibitory interactions between CBP 
and these chemokines, whereas these interactions had previously been observed (Seet et al., 
2003; Counago et al., 2015; Sharif et al., 2016).  
For XCL1, no indication of binding was observed with both conjugated, and unconjugated CBP, 
thereby implying a failing in the ELISA protocol occurred. Interestingly, the affinity of CBP 
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for this chemokine is weaker (0.6 nM, determined via ELISA) for C chemokines than for the 
CC and CXC chemokines, as observed by ELISA (Seet et al., 2003; Counago et al., 2015). The 
antibodies utilised in the original XCL1 ELISA were no longer available, and it may be that 
CBP is unable to out-compete the replacement antibodies in the adjusted protocol. 
In the case of CXCL4, the effect was opposite to that expected, with increased levels of 
chemokine correlating with increasing levels of CBP. This result could potentially be due to the 
introduction of CXCL4 into the system. Counago et al. (2015) has shown that CBP, when 
expressed in HEK293s in the presence of serum, can be purified in complex with CXCL4. 
Although within the current study, CBP was produced under serum free conditions, these 
findings indicate that some of the purified protein was coupled to CXCL4, and that this could 
be detected in the ELISA.    
As vCBPs bind with high affinity to a broad range of inflammatory chemokines, the 
fluorescently-conjugated version would be useful in the detection of inflammatory diseases. To 
test this, a monocyte (THP-1) cell line known to secrete several inflammatory chemokines upon 
activation and stimulation was utilised (Park et al., 2007). To model inflammation in these cells, 
this study utilised PMA, which activates P2X7R and AMPK/MAPK pathways that commence 
differentiation of monocytes to macrophages (Lin et al., 2018), and LPS, which stimulates 
TLR4 and Myd88 activation of NFkB and the subsequent pro-inflammatory gene expression 
(Lu et al., 2008). Under these conditions, THP-1 cells were shown to secrete numerous 
inflammatory mediators including CCL2, CCL5, and TNFα, all of which all can be indicative 
of an inflammatory response (Wolf et al., 2017; Benamar et al., 2008; Popa et al., 2007). The 
degree of protein expression by THP-1 cells noted in this study largely mimicked that observed 
in previous literature, in which LPS stimulated THP-1 cells were utilised (Haberstroh et al., 
2002; Tai et al., 2013).  
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Through the utilisation of an antibody selective for CCL2, it can be assumed that any binding 
observed is exclusively through interactions of this protein. Using immunofluorescent 
cytometry, the labelled antibody was able to bind to THP-1 cells immobilised on coverslips to 
an extent which was proportional to the level of secreted CCL2 produced under different 
activating conditions. Labelled CBP was also able to bind THP-1 cells, but the levels did not 
correlate with the secreted CCL2. This finding indicates that although the labelled CBP can be 
utilised to detect monocytes, it may lack the specificity needed to detect chemokines under 
inflammatory conditions, as observed with the anti-CCL2 antibody.  
As the amount of labelled CBP detected on the cells did not correlate with the levels of secreted 
CCL2 or anti-CCL2 antibody detected, attempts were made to examine if CBP was in fact 
capable of binding CCL2 expressed by the cells, via blocking the CBP-chemokine interaction. 
Blocking this interaction was undertaken in two ways. The first utilised unlabelled antibody or 
CBP to pre-bind chemokine on/in cells prior to the incubation of the labelled proteins with cells. 
The second used pre-binding of CCL2 to the labelled antibody or CBP prior to incubation with 
cells. It was hypothesised that blocking of the CCL2 binding site, either with proteins which 
also bind CCL2, or pre-binding proteins with CCL2, would be indicative of CCL2 specific 
interaction. Whilst the unlabelled anti-CCL2 antibody was able to block binding to the cells by 
the labelled version of itself, the unlabelled CBP failed to block this interaction. In addition, the 
binding of the labelled CBP to cells was not inhibited by either the antibody or CBP. Similarly, 
whilst pre-binding CCL2 with the labelled antibody reduced the level of fluorescence in 
samples, no such reduction was observed with the labelled CBP. These findings illustrated that 
the fluorescence detected following incubation with the labelled antibody was specific for 
CCL2, as expected. By contrast, the evidence suggests the CCL2 is not (at least) the primary 
target of CBP in this setting. It should be noted that in each case, the blocking action of the 
unlabelled antibody or chemokine did not completely inhibit the detection of THP-1-expressed 
CCL2 by the labelled antibody. This could be further examined by utilising increased amount 
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of blocking protein to saturate all expressed chemokine, thereby giving more comprehensive 
results.  
Although fluorescence was observed in the cells with labelled CBP, there is a possibility that 
the binding is non-specific in nature. These samples were fixed as to immobilise cells and 
proteins for later analysis. Methanol fixation was use, which may alter the tertiary structure of 
a protein as it impacts charges within the protein, resulting in the solubilisation of fixed samples 
(Rolls, 2012). As an antibody is generally able to access the small epitope, it can often maintain 
binding to a denatured or partially denatured protein (Bass et al., 2016). CBP-chemokine 
interactions require extensive interactions, engaging approximately 25% of the chemokine 
surface (Counago et al., 2015). As methanol fixation may alter the chemokine tertiary structure, 
it is possible the CBP-chemokine interaction is no longer facilitated. Investigation utilising non-
fixed cells was not undertaken, primarily due to initial difficulties regarding cell adherence and 
a lack of cells remaining after the various incubation steps. There are other techniques for 
fixation which may facilitate charge-based binding better such as formalin fixation, of which 
presents a less altered protein (Matsuda et al., 2011). CBP detection of chemokines may also 
be more likely in native human samples such as unfixed cytology samples (synovial fluid, 
cervical smears) or frozen tissues (cancer biopsies) (Villanueva and Schumacher, 1987; Arbyn 
et al., 2008; Brender et al., 2005; Bas et al., 2002). Further study is therefore needed to assess 
whether CBP would show potential utility in these scenarios.  
With the observed CBP binding not presently supported to be chemokine-based, there is another 
potential interaction which could explain the findings. During the inflammatory response, the 
involvement of GAGs is understood to be a supportive role. GAGs bind to and present 
inflammatory mediators including chemokines to cells, thereby facilitating chemokine 
receptor/ligand interactions and promoting the formation of a chemotactic gradient (Thompson 
et al., 2017). HS is an important GAG, of which assists with the formation of the chemokine 
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gradient, thereby promoting leukocyte extravasation (Farrugia et al., 2018). Alongside the 
ability of several vCBPs to bind chemokines, some also possess the ability bind GAGs (Lucas 
and McFadden, 2004). It has been proposed that the vCBP-GAG interaction could either 
prevent the formation of the chemotactic gradient, occurring when chemokines bind to GAGs 
on endothelial cells, or, to create their own gradient on endothelial cells enhancing their own 
ability to capture chemokines (Proudfoot et al., 2003). The vCBP used in this study has a 
proposed GAG binding site, being a dense, positively charged groove located on β-sheet I which 
shares distinct homology with the characterised GAG binding site of M-T1 (Counago et al., 
2015; Seet et al., 2001). However, experimental attempts to assess CBP binding with heparin 
(a polysaccharide closely related in structure to HS) have so far failed to indicate any 
interaction. It was hypothesised that by pre-binding labelled CBP with heparin, any GAG 
binding site would be occupied, thereby blocking the ability of CBP to interact with GAGs on 
the monocytes. Interestingly, upon heparin pre-binding there was a reduction in the amount of 
labelled CBP detected on THP-1 cells; an effect not observed by the anti-CCL2 antibody. This 
assay is therefore the first experimental evidence to potentially demonstrate an interaction 
between CBP and heparin.  
Although interesting experimentally, the ability for vCBPs to interact with GAGs arises a 
potentially detrimental feature for diagnostic utilisation. For diagnostics specificity is key, 
however with GAGs lining almost all cell types there may be a risk of non-specific binding, 
therefore an inability to accurately identify disease-related chemokine activity. Considering the 
potential application of these proteins in imaging protocols, this would most certainly lead to a 
loss of specificity, being comparable to failures of image-based chemokine receptor targeting 
(Nishizawa et al., 2010). However, vCBPs such as M-T7 and M3 are not indicated to bind 
directly with GAGs (Lalani et al., 1997; Alexander-Brett and Fremont, 2007) and their use may 
overcome the limitations of GAG-binding vCBPs.  
76 
 
Alternately, some research suggests that upregulated heparinase, of which breaks down 
heparins for cleavage from the cell surface, is observed in inflammatory diseases such as IBD 
(Waterman et al., 2007; Day and Forbes, 1999). Heparinase cleavage of HS is also known to 
promote the dissemination of the inflammatory cells through the body, facilitating the 
metastasis of numerous cancers including pancreatic, breast, colon, and lung (Vlodavsky et al., 
2001; Vlodavsky et al., 2012). Thereby, a potentially beneficial role of targeting GAGs for 
prognosis/diagnosis of cancer metastasis may exist. However, further characterisation of GAG 
interactions with vCBPs would be required to investigate their potential use in this setting. 
As CBP exhibits binding across several chemokines, the expression of other chemokines within 
the assay may impact upon its sensitivity. For example, CCL5 was observed to exhibit 
constitutive expression by the THP-1 monocytes, regardless of treatment and at earlier time 
points compared with CCL2. Previous SPR findings indicate that CBP has a higher affinity for 
CCL5 compared to CCL2 (Lateef et al. 2009) when utilising mouse chemokines. Similarly, in 
the current study, the IC50 of CBP for CCL5 was greater than that observed for CCL2 when 
using human chemokines (0.4nM to 0.8nM, as observed by ELISA). This finding suggests, that 
if labelled CBP is predominantly binding CCL5, it may not be possible to detect substantial 
differences across the time points as the labelled protein may not have reached saturating levels 
for the amount of available chemokine. This could be further investigated by utilising CCL5-
specific antibodies, or the CCL5 protein itself, to block CBP binding to the cells in this system. 
Monocytes have also been shown to express a multitude of other chemokines under constitutive 
and inflammatory conditions (Harrison et al., 2005), with CBP likely binding to numerous of 
these chemokines (Counago et al., 2015; Sharif et al., 2016). A similar approach could be 
utilised to block these chemokine-specific interactions to better assess their involvement in the 
CBP binding observed in this study. Alternately, utilising differing cell lines for which 
chemokine expression is more limited and specific could provide these insights. 
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For more extensive characterisation of potential applications for CBP in diagnostics, varying 
tissues and tissue states should be investigated. This study utilised a monocytic cell line of 
which is known to be a potent expresser of chemokines (Park et al., 2007). Comparatively, 
experimental and clinical testing for inflammation involves numerous sample types of which 
all possess drastically differing characteristics, including cancer cells, blood or synovial 
samples, and frozen biopsies. Other sample types may indicate more successful application of 
vCBPs for the detection of chemokines. However, further consideration would be required as 
the expression of GAGs may be biasing the presence of a true chemokine-vCBP interaction. 
4.2 Other Uses for CBP 
This study also examined the potential utilisation of labelled CBP within western blotting 
protocols. Whilst the labelled anti-CCL2 antibody could detect reduced protein as hypothesised, 
CBP was unable to detect chemokine in this state, likely due to reduction of the protein 
disrupting its tertiary structure. Utilising chemokines which have not been reduced by 2-ME, 
thereby retaining their tertiary structure, would be the next step in examining the potential 
application of vCBPs in western blotting protocols (Homma et al., 2004). Similarly, assessing 
chemokines run on native gels without SDS would allow for the retention of chemokine charge, 
therefore potentially allowing vCBP binding (Gudiksen et al., 2006).  
ELISA protocols utilise multiple antibody interactions to provide a common methodology for 
protein detection across both scientific research and clinical diagnostics. The replacement of 
capture or detection antibodies in the ELISA protocol with a vCBP could increase the sensitivity 
and usability of the assay. This study first investigated the use of native CBP as a substitute for 
the capture antibody. The use of a broad-spectrum binding protein would eliminate the need for 
chemokine-specific capture antibodies, potentially allowing it to be used across arrange of 
chemokine-specific ELISAs. As CBP exhibited high affinity chemokine binding when coupled 
to SPR chips (Lateef et al., 2009; Counago et al., 2015; Sharif et al., 2016), this suggests the 
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capture of chemokines via CBP coated to an ELISA plate may be possible.  A linear relationship 
in the amount of human CCL2 chemokine standard was observed similarly to that of the capture 
antibody, suggesting the chemokine also successfully bound to CBP-coated wells. This was 
consistent with SPR findings in which charge-based interactions between the CBP and chip 
were shown not occlude the chemokine binding site. Interestingly, this finding also suggests 
CBP-bound chemokine can form a complex with the detection antibody simultaneously. As the 
detection antibody used was a monoclonal antibody, it binds with a singular epitope on the 
chemokine. The immunogenic epitope for the detection antibody was unknown, however based 
on the theoretical CBP-chemokine-antibody complex formed, the epitope likely lies outside the 
chemokine receptor-binding face occluded with CBP interaction. An important next step would 
be a direct comparison utilising equimolar amounts of the commercial capture antibody and 
CBP to ascertain their relative sensitivity for human CCL2 in this assay. As the antibody utilised 
was part of a kit, the concentration of the antibody was not provided, so this was unable to be 
completed without purchasing the antibody clone at a known concentration. 
This ELISA experiment was only undertaken with human CCL2, thereby to assess the true 
utility of CBP further examination is required with additional chemokines. As observed with 
the CCL2 ELISA, CBP will need to be paired with a detection antibody that recognises the 
binding epitope outside of the chemokine domain bound by CBP.  Predominantly, CBP binds 
chemokines at their receptor-binding face, therefore ideal detection antibodies would be those 
that bind chemokines without neutralising function. The epitope an antibody recognises, and 
the potential neutralising capabilities of the antibody are not always known, therefore screening 
would be required to identify those compatible with the vCBP in an ELISA scenario.  
If this protocol were to be investigated further, the broad-spectrum binding characteristic of 
CBP would need to be tested in samples with a mixed pool of chemokines (such as synovial or 
serum samples). It is possible that in this scenario, the specific chemokine to be detected may 
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only represent a minor fraction of that captured by CBP, thus reducing the sensitivity of the 
assay. Similarly, if GAGs are in the system there may be a potential interaction with CBP. As 
such, the use of CBP as a broad-spectrum detection antibody substitute may be more 
appropriate.  
Utilising a vCBP which could bind chemokines already captured by the specific capture 
antibody would both maintain the specificity for detection, and also eliminate the need for 
specific detection antibodies across numerous ELISA protocols (Clark et al., 1986). However, 
as mentioned above, investigation could be required to identify capture antibodies that bind 
chemokines whilst leaving the domain needed for CBP interactions free. To assess whether this 
was possible, the ability of CBP to directly compete with the detection antibody in a human 
CCL2 ELISA was examined. The assumption being that if it could, it was able to bind the 
chemokine in complex with the capture antibody. Interestingly, at high concentrations of the 
vCBP there was blocking of the detection antibody observed. Although suggesting the 
formation of a capture antibody-chemokine-CBP complex, there is also a distinct possibility 
that CBP is outcompeting the antibody for the chemokine. To further investigate this theory, 
complex assembly could be analysed using immunoprecipitation, SDS-page, or western 
blotting. If the formation of a CBP-chemokine-antibody complex is shown, the next step would 
be repeat the ELISA with CBP to determine whether the FLAG-tag could be detected with the 
anti-FLAG M2-HRP-conjugated antibody. Alternatively, CBP could be conjugated directly 
with biotin or HRP and then assessed. 
4.3 Summary 
The aim of this study was to develop and investigate the use of CBP as potential diagnostic tool 
for inflammation. If successful, this study would suggest there is potential application for all 
vCBPs as diagnostic tools, providing a vast range of potential binding profiles to utilise for 
detection of chemokines for diagnostics (Lucas and McFadden, 2004).   
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From this study, there is not a clear indication of efficacy for labelled CBP in immuno-
fluorescent cytology. Although there were indications of positive findings with this protocol, 
without further characterisation an assumption cannot be made as to whether the vCBP would 
make a useful diagnostic. This study was unable to confirm that CBP could bind chemokines 
fixed on/in monocytes, and there was only an indication of a heparin-based interaction. 
Irrespective of the nature of binding, the labelled antibody showed a higher sensitivity for the 
chemokine, therefore being a more sensitive potential diagnostic tool than CBP. Although there 
was a suggestion of heparin binding observed with CBP, there may be little use for a heparin-
based diagnostic tool. As GAGs are expressed on almost all cell types, the introduction of the 
labelled CBP may not be beneficial in detecting inflammation (Couchman and Pataki, 2012).  
From this study, the most promising application of vCBPs within biological testing comes in 
the form of adapted ELISA protocols. With the development of vCBPs as a dynamic detection 
antibody substitute, the ability to utilise a singular detection protein across multiple ELISAs 
could provide both an increase in efficiency, and a decrease in cost. Similarly, the use of a 
specific capture antibody could have utility for the detection of several chemokines. Although 
matching between capture antibodies and vCBP would be required to ensure non-overlapping 
epitopes, the present study does indicate some potential.  
As indicated within the current study, the physical state of the chemokine is likely a huge factor 
in which determines the applicability of vCBPs for detection. In ELISA techniques and native 
human samples, the chemokines tested are neither fixed nor altered. As several tests for 
chemokines in biological samples use serum and synovial testing (as with RA), or utilise frozen 
tissues (as with cancer), the application of vCBPs to detect native chemokines warrants further 
investigation (Villanueva and Schumacher, 1987; Arbyn et al., 2008; Brender et al., 2005; Bas 
et al., 2002). While the use of vCBPs as broad-spectrum chemokine detectors in diagnostic 
procedures is an interesting concept, any potential benefits of this approach are yet to be proven.  
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Supplementary Figures  
Supplementary Figure 1. CBP appears to be introducing CXCL4 into the ELISA, resulting 
in opposing binding curve. Various concentrations of conjugated or native CBP were 
incubated with human CXCL4. Unbound chemokine was then detected using a competition 
ELISA. The conjugated CBP was prepared using protocol 1. Results are presented as the 
percentage of unbound chemokine, normalised to a CXCL4 only control, without the 
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